

30.03.2022

11:30 - 13:00 Amgen - Targeting KRASG12C: A new era for patients with advanced NSCLC South Hall 2

Moderation: S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

11:30 - 11:35 **Welcome and introduction**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

11:35 - 11:50 **KRASG12C inhibition: A major landmark in 2nd line treatment of patients with advanced NSCLC**

J. De Langen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

11:50 - 12:05 **The turning point: Practical considerations when emerging biomarkers become actionable**

K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB

12:05 - 12:20 **Forward thinking: Future perspectives in targeting KRAS in NSCLC**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

12:20 - 12:35 **Panel discussion - Managing patients with *KRAS*^{G12C}-mutant NSCLC: Real-world perspectives**

A. Speakers, Prague, CZ

12:35 - 12:55 **Audience Q&A**

A. Speakers, Prague, CZ

12:55 - 13:00 **Summary and close**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

11:30 - 13:00	Mirati Therapeutics, Inc. - Tailoring therapy: Emerging treatment options in NSCLC Moderation: M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE	Forum Hall
11:30 - 11:35	Welcome and introductions <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
11:35 - 11:55	The evolving landscape of advanced NSCLC therapy <u>R. Juergens</u> , JCC - Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, CA	
11:55 - 12:15	Addressing resistance to checkpoint inhibitors in NSCLC <u>F. Cappuzzo</u> , IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT	
12:15 - 12:35	Targeting KRAS-driven NSCLC <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
12:35 - 13:00	Q&A and summary <u>A. Speakers</u> , Prague, CZ	
13:30 - 14:05	Welcome to ELCC 2022 and Heine H. Hansen Award 2022 Keynote lecture Moderation: L. Hendriks ¹ , N. Girard ² , ¹ Maastricht University Medical Center (MUMC), Maastricht, NL, ² Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR	Congress Hall
13:30 - 13:32	Opening and welcome <u>N. Girard</u> ¹ , L. Hendriks ² , ¹ Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR, ² Maastricht University Medical Center (MUMC), Maastricht, NL	
13:32 - 13:35	Introduction to the Heine H. Hansen Award 2022 <u>L. Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, NL	
13:35 - 14:05	The tissue is (still) the issue <u>F. Hirsch</u> , New York, US	

14:15 - 15:45	Implementation of screening programmes in Europe	South Hall 2
	Moderation: D.R. Baldwin ¹ , L. Montuenga ² , ¹ City Hospital Campus - Nottingham University Hospitals NHS Trust, Nottingham, GB, ² Clinica Universidad de Navarra, Pamplona, ES	
14:15 - 14:35	Where do we stand?	
	<u>M. Oudkerk</u> , University of Groningen, Groningen, NL	
14:35 - 14:55	Reading guidelines	
	<u>N. Bogot</u> , Shaare Zedek Medical Center, Jerusalem, IL	
14:55 - 15:15	Nodule investigation	
	<u>D.R. Baldwin</u> , City Hospital Campus - Nottingham University Hospitals NHS Trust, Nottingham, GB	
15:15 - 15:35	Biomarkers in screening effort	
	<u>L. Montuenga</u> , Clinica Universidad de Navarra, Pamplona, ES	
15:35 - 15:45	Q&A	
	A. Speakers, Prague, CZ	

14:15 - 15:45	What to do after immunotherapy failure and when to avoid immunotherapy in early disease NSCLC	Congress Hall
	Moderation: R.S. Herbst ¹ , J. Zugazagoitia ² , ¹ Yale University School of Medicine, New heaven, US, ² Hospital Universitario 12 de Octubre, Madrid, ES	
14:15 - 14:25	Case presentation	
	<u>J. Zugazagoitia</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
14:25 - 14:40	When to avoid immunotherapy in early disease	
	<u>M. Wislez</u> , Paris, FR	
14:40 - 14:55	What is the role of chemotherapy and antiangiogenics?	
	<u>R.S. Herbst</u> , Yale University School of Medicine, New heaven, US	
14:55 - 15:10	IO rechallenge	
	<u>G. Mountzios</u> , Henry Dunant Hospital Centre, Athens, GR	
15:10 - 15:25	Novel approaches	
	<u>J. Zugazagoitia</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
15:25 - 15:45	Discussion	
	A. Speakers, Prague, CZ	

14:15 - 15:45	Not so small anymore: New therapies and cutting-edge science to guide the care of patients with small cell lung cancer	Forum Hall
	Moderation: J. Naidoo ¹ , B. Drapkin ² , ¹ Sidney Kimmel Comprehensive Cancer Center at John Hopkins University, Baltimore, MD, USA and Beaumont Hospital and RCSI University of Health Sciences, Dublin, IE, ² UT Southwestern Medical Center, Dallas, US	
14:15 - 14:35	First shot on goal is the most important: Updates on first line therapy for limited stage and extensive stage SCLC	
	J. Naidoo, Sidney Kimmel Comprehensive Cancer Center at John Hopkins University, Baltimore, MD, USA and Beaumont Hospital and RCSI University of Health Sciences, Dublin, IE	
14:35 - 14:55	Battling recurrent SCLC: Emerging therapies for platinum refractory disease	
	G. Lo Russo, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT	
14:55 - 15:15	Delivering on the promise of precision medicine in SCLC: Emerging molecular sub-types	
	B. Drapkin, UT Southwestern Medical Center, Dallas, US	
15:15 - 15:35	Transformed SCLC: Emerging science on histologic subtype switching	
	T. Sen, Memorial Sloan Kettering Cancer Center, New York, US	
15:35 - 15:45	Q&A	
	A. Speakers, Prague, CZ	
14:15 - 15:15	Mini Oral session 2	Club A
14:15 - 14:20	3MO - First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small-cell lung cancer: Updated overall survival results from the phase 3 CameL-sq trial	
	C. Zhou ¹ , Y. Cheng ² , J. Chen ³ , X. Xu ⁴ , G. Chen ⁵ , Y. Pan ⁶ , Y. Fang ⁷ , Q. Wang ⁸ , Y. Huang ⁹ , W. Yao ¹⁰ , R. Wang ¹¹ , X. Li ¹² , W. Zhang ¹³ , Y. Zhang ¹⁴ , J. Shi ¹⁵ , P. Cao ¹⁶ , D. Wang ¹⁷ , D. Lv ¹⁸ , H. Luo ¹⁹ , Z. Yang ²⁰ , ¹ Shanghai Pulmonary Hospital, Shanghai, CN, ² Jilin Cancer Hospital, Changchun, CN, ³ Hunan Cancer Hospital, Changsha, CN, ⁴ Northern Jiangsu People's Hospital, Yangzhou, CN, ⁵ Harbin Medical University Cancer Hospital, Harbin, CN, ⁶ The First Affiliated Hospital of University of Sciences and Technology of China, Hefei, CN, ⁷ Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, CN, ⁸ Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, CN, ⁹ Yunnan Cancer Hospital & The Third Affiliated Hospital of Kunming Medical University & Yunnan Cancer Centre, Kunming, CN, ¹⁰ Sichuan Provincial Cancer Hospital, Chengdu, CN, ¹¹ Anhui Chest Hospital, Hefei, CN, ¹² The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ¹³ The First Affiliated Hospital of Nanchang University, Nanchang, CN, ¹⁴ Shaanxi Provincial Cancer Hospital, Xi'an, CN, ¹⁵ Linyi Cancer Hospital, Linyi, CN, ¹⁶ The Third Xiangya Hospital of Central South University, Changsha, CN, ¹⁷ Chongqing University Cancer Hospital, Chongqing, CN, ¹⁸ Taizhou Hospital of Zhejiang Province, Taizhou, CN, ¹⁹ Jiangxi Cancer Hospital, Nanchang, CN, ²⁰ Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, CN	

- 14:20 - 14:25 **4MO - Final Overall Survival (OS) Data of Sintilimab Plus Pemetrexed (SPP) and Platinum as First-Line (1L) Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (AMnsqNSCLC) in the Phase 3 ORIENT -11 Study**
- Y. Yang¹, Z. Wang², J. Fang³, Q. Yu⁴, B. Han⁵, S. Cang⁶, G. Chen⁷, X. Mei⁸, Z. Yang⁹, V. Stefaniak¹⁰, Y. Lin¹⁰, S. Wang¹¹, W. Zhang¹¹, L. Sun¹¹, L. Zhang¹, ¹State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, CN, ²Shandong Cancer Hospital, Jinan, Shandong, CN, ³Peking University Cancer Hospital, Beijing, CN, ⁴Affiliated Tumor Hospital of Guangxi Medical University, Nanning City, CN, ⁵Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ⁶The Henan Province Hospital of Zhengzhou University, Zhengzhou, CN, ⁷Harbin Medical University Cancer Hospital, Harbin, CN, ⁸Anhui Provincial Hospital, Hefei, CN, ⁹Affiliated Hospital of Guangdong Medical University, Zhanjiang, CN, ¹⁰Eli Lilly and Company, Indianapolis, US, ¹¹Innovent Biologics, Inc., Suzhou, CN
- 14:25 - 14:30 **5MO - Patient-reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON**
- E. Garon¹, B.C. Cho², A. Luft³, J. Alatorre-Alexander⁴, S.L. Geater⁵, D. Trukhin⁶, S.-W. Kim⁷, G. Ursol⁸, M. Hussein⁹, F.L. Lim¹⁰, C.-T. Yang¹¹, L.H. Araujo¹², H. Saito¹³, N. Reinmuth¹⁴, N. Medic¹⁵, H. Mann¹⁵, X. Shi¹⁶, S. Peters¹⁷, T. Mok¹⁸, M. Johnson¹⁹, ¹David Geffen School of Medicine at UCLA, Santa Monica, US, ²Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ³Leningrad Regional Clinical Hospital, St Petersburg, RU, ⁴Health Pharma Professional Research, Mexico City, MX, ⁵Prince of Songkla University, Songkhla, TH, ⁶Odessa Regional Oncological Dispensary, Odessa, UA, ⁷Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁸Acinus, Kropyvnytskyi, UA, ⁹Florida Cancer Specialists – Sarah Cannon Research Institute, Leesburg, US, ¹⁰Queen Mary University of London, London, GB, ¹¹Chang Gung Memorial Hospital, Taoyuan City, TW, ¹²Instituto Nacional de Cancer-INCA, Rio de Janeiro, BR, ¹³Kanagawa Cancer Center, Yokohama, JP, ¹⁴Asklepios-Fachklinikum, Gauting, DE, ¹⁵AstraZeneca, Cambridge, GB, ¹⁶AstraZeneca, Gaithersburg, US, ¹⁷CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ¹⁸Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK, ¹⁹Sarah Cannon Research Institute, Nashville, US
- 14:30 - 14:35 **6MO - Pembrolizumab plus ipilimumab or placebo in previously untreated metastatic NSCLC With PD-L1 tumor proportion score ≥50%: KEYNOTE-598 3-year follow-up**
- D. Rodriguez Abreu¹, M. Reck², M.A.N. Sendur³, K. Park⁴, D.H. Lee⁵, I. Cicin⁶, P.F. Yumuk⁷, F.J. Orlandi⁸, T.A. Leal⁹, N. Soparattanapaisarn¹⁰, A. Langleben¹¹, R. Califano¹², B. Medgyasszay¹³, T.-C. Hsia¹⁴, G.A. Otterson¹⁵, T. Woods¹⁶, E. Jensen¹⁶, A. Samkari¹⁶, M. Boyer¹⁷, ¹Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, ES, ²Krankenhaus Grosshansdorf, Grosshansdorf, DE, ³Ankara Yildirim Beyazit University, Faculty of Medicine and Ankara City Hospital, Ankara, TR, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁵Asan Medical Center, Seoul, KR, ⁶Trakya University, Edirne, TR, ⁷Marmara University School of Medicine, Istanbul, TR, ⁸Orlandi-Oncología, Providencia, CL, ⁹University of Wisconsin Carbone Cancer Center, Madison, US, ¹⁰Mahidol University, Siriraj Hospital, Bangkok, TH, ¹¹St. Mary's Hospital – ODIM, McGill University Department of Oncology, Montreal, CA, ¹²The

Christie NHS Foundation Trust, and Division of Cancer Sciences, University of Manchester, Manchester, GB, ¹³Veszprém County Lung Hospital, Farkasgyepu, HU, ¹⁴China Medical University and China Medical University Hospital, Taichung, TW, ¹⁵Ohio State University-James Comprehensive Cancer Center, Columbus, US, ¹⁶Merck & Co., Inc., Kenilworth, US, ¹⁷Chris O'Brien Lifehouse, Camperdown, AU

14:35 - 14:45 **Invited Discussant of 3MO, 4MO, 5MO and 6MO**

L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

14:45 - 14:50 **2MO - Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC**

S. Lu¹, J. Fang², X. Li³, L. Cao⁴, J. Zhou⁵, Q. Guo⁶, Z. Liang⁷, Y. Cheng⁸, L. Jiang⁹, N. Yang¹⁰, Z. Han¹¹, J. Shi¹², Y. Chen¹³, H. Xu¹⁴, H. Zhang¹⁵, G. Chen¹⁶, R. Ma¹⁷, S. Sun¹⁸, Y. Fan¹⁹, S. Weiguo²⁰, ¹Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN, ²Peking University Cancer Hospital & Institute, Beijing, CN, ³The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ⁴The First Affiliated Hospital of the University of Science and Technology of China, Anhui Provincial Hospital, Hefei, CN, ⁵The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, ⁶Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, CN, ⁷West China School of Medicine and West China Hospital, Sichuan University, Chengdu, CN, ⁸Jilin Cancer Hospital, Changchun, CN, ⁹Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ¹⁰Hunan Cancer Hospital, Affiliated Tumor Hospital of Xiangya Medical School of Central South University, Changsha, CN, ¹¹The Affiliated Cancer Hospital of Xinjiang Medical University, Urumuqi, CN, ¹²Linyi Cancer Hospital, Linyi, CN, ¹³Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, CN, ¹⁴The Second Affiliated Hospital of Nanchang University, Nanchang, CN, ¹⁵Tangdu Hospital, Fourth Military Medical University, Xi'An, CN, ¹⁶Affiliated Cancer Hospital of Harbin Medical University, Harbin, CN, ¹⁷Liaoning Cancer Hospital, Shenyang, Liaoning, CN, ¹⁸Xuzhou Central Hospital, Xuzhou, CN, ¹⁹Zhejiang Cancer Hospital, Hangzhou, CN, ²⁰HUTCHMED, Shanghai, CN

14:50 - 14:55 **7MO - Oritinib (SH-1028), a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: results of a single-arm phase II trial**

C. Zhou¹, A. Xiong¹, J. Zhao², W. Li³, M. Bi³, J. Chen⁴, K. Li⁴, L. Miao⁵, Y. Mao⁶, D. Wang⁷, C. Liu⁸, A. Zeng⁹, R. Li¹⁰, Y. Pan¹¹, Y. Hu¹², X. Zhang¹³, H. Niu¹⁴, Y. Du¹⁵, Y. Sun¹⁶, Z. Liu¹⁷, ¹Shanghai Pulmonary Hospital, Shanghai, CN, ²Xuzhou Central Hospital, Xuzhou, CN, ³The First Affiliated Hospital of Bengbu Medical College, Bengbu, CN, ⁴Hunan Cancer Hospital, Changsha, CN, ⁵Nanjing Drum Tower Hospital, Nanjing, CN, ⁶The First Affiliated Hospital of Henan University of Science and Technology, Luoyang, CN, ⁷Chongqing University Cancer Hospital, Chongqing, CN, ⁸Center Hospital Affiliated to Xinjiang Medical University, Wulumuqi, CN, ⁹Guangxi Medical University Affiliated Tumor Hospital, Nanning, CN, ¹⁰Baoding NO.2 Central Hospital, Baoding, CN, ¹¹The First Affiliated Hospital of University of Sciences and Technology of China, Hefei, CN, ¹²Hubei Cancer Hospital, Wuhan, CN, ¹³Nantong Cancer Hospital, Nantong, CN, ¹⁴The First Affiliated Hospital of Xinxiang Medical College, Xinxiang, CN, ¹⁵The First Affiliated Hospital of Anhui Medical University, Hefei, CN, ¹⁶Jinan Central Hospital Affiliated to Shandong University, Jinan, CN, ¹⁷Jiangxi Cancer Hospital, Nanchang, CN

14:55 - 15:00	<p>8MO - The efficacy and safety of TQ-B3101 monotherapy in the first line treatment in patients with ROS1 positive non-small cell lung cancer</p> <p><u>S. Lu</u>¹, H. Pan², L. Wu³, Y. Yao⁴, J. He⁵, Y. Wang⁶, X. Wang⁷, X. Wang⁸, X. Cai⁹, Y. Yu¹⁰, Z. Ma¹¹, X. Min¹², Z. Yang¹³, L. Cao¹⁴, H. Yang¹⁵, Y. Shu¹⁶, W. Zhuang¹⁷, S. Cang¹⁸, J. Fang¹⁹, K. Li²⁰, ¹Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN, ²Sir Run Run Shaw Hospital, Zhejiang University, Zhejiang, CN, ³Hunan Cancer Hospital (The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University), Changsha, CN, ⁴The First Affiliated Hospital of Xi'an Jiaotong University, Xian, CN, ⁵The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN, ⁶National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁷Qilu Hospital of Shandong University, Jinan, CN, ⁸The First Affiliated Hospital/School of Clinical Medicine of Guangdong Pharmaceutical University, Guangzhou, CN, ⁹Sun Yat-sen University Cancer Center, Guangzhou, CN, ¹⁰Harbin Medical University Cancer Hospital, Harbin, CN, ¹¹Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, CN, ¹²Anhui Chest Hospital, Hefei, CN, ¹³Affiliated Hospital of Guangdong Medical University, Zhanjiang, CN, ¹⁴The First Affiliated Hospital of the University of Science and Technology of China, Anhui Provincial Hospital, Hefei, CN, ¹⁵Xiangya Hospital Central South University, Changsha, CN, ¹⁶Jiangsu Province People's Hospital, Nanjing, CN, ¹⁷Fujian Cancer Hospital and Fujian Medical University Cancer Hospital, Fuzhou, CN, ¹⁸The Henan Province Hospital of Zhengzhou University, Zhengzhou, CN, ¹⁹Peking University Cancer Hospital & Institute, Beijing, CN, ²⁰Tianjin Medical University Cancer Institute and Hospital, Tianjin, CN</p>
15:00 - 15:10	<p>Invited Discussant of 2MO, 7MO and 8MO</p> <p><u>N. Leighl</u>, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA</p>
15:10 - 15:15	<p>Q&A</p> <p>A. Speakers, Prague, CZ</p>

16:00 - 17:30	Telemedicine in lung cancer: What to do in 2022?	South Hall 2
	Moderation: N. Leighl ¹ , F. Denis ² , ¹ UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ² ILC Jean Bernard, Le Mans, FR	
16:00 - 16:20	Improving outcome through electronic surveillance	
	<u>F. Denis</u> , ILC Jean Bernard, Le Mans, FR	
16:20 - 16:40	Applications of telehealth in lung cancer	
	<u>M. Sivanandan</u> , Nottingham, GB	
16:40 - 17:00	Telescreening, here we come!	
	<u>N. Leighl</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
17:00 - 17:20	Improving clinical trials reporting through telemedicine	
	<u>L. Coate</u> , University Hospital Limerick, Limerick, IE	
17:20 - 17:30	Q&A	
	A. Speakers, Prague, CZ	
16:00 - 17:30	Personalised treatment of lung cancer brain metastases	Club A
	Moderation: J. Remon Masip ¹ , L. Hendriks ² , ¹ HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES, ² Maastricht University Medical Center (MUMC), Maastricht, NL	
16:00 - 16:10	Case presentation: A patient with driver mutation	
	<u>A. Levy</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
16:10 - 16:25	TKI in patients with oncogene driven NSCLC	
	<u>J. Remon Masip</u> , HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES	
16:25 - 16:40	Immunotherapy for non-oncogene addicted NSCLC	
	<u>L. Hendriks</u> , Maastricht University Medical Center (MUMC), Maastricht, NL	
16:40 - 16:55	Sequencing of radiotherapy and systemic therapy	
	<u>A. Levy</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
16:55 - 17:10	When to incorporate surgery in the treatment of lung cancer brain metastases?	
	<u>P. Métellus</u> , Marseille, FR	
17:10 - 17:30	Discussion	
	A. Speakers, Prague, CZ	

16:00 - 17:30	New insights in the treatment of geriatric patients	Forum Hall
	Moderation: L. Decoster ¹ , R. Ferrara ² , ¹ UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE, ² Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
16:00 - 16:20	Biological hallmarks of ageing: Potential therapeutic targets?	
	<u>R. Ferrara</u> , Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
16:20 - 16:40	Geriatric assessment in the chest MDT	
	<u>L. Decoster</u> , UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE	
16:40 - 17:00	Can AI help guide diagnosis and treatment of special cancer populations such as the elderly?	
	<u>A. Dekker</u> , Maastricht, Maastricht, NL	
17:00 - 17:20	What past and future trials tell us	
	<u>R. Corre</u> , CH de Cornouaille - Hopital Laennec, Quimper, FR	
17:20 - 17:30	Q&A	
	A. Speakers, Prague, CZ	
16:00 - 17:30	Thymic tumours	Congress Hall
	Moderation: E. Ruffini ¹ , N. Girard ² , ¹ University of Turin, Torino, IT, ² Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR	
16:00 - 16:20	Update on the Staging Project for the 9th edition of the TNM staging system of thymic tumors	
	<u>E. Ruffini</u> , University of Turin, Torino, IT	
16:20 - 16:40	Early-stage tumors: What is the optimal surgical management in 2022?	
	<u>V. Fang</u> , Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN	
16:40 - 17:00	Locally advanced tumors: The key word is multidisciplinary	
	<u>A. Rimner</u> , Memorial Sloan Kettering Cancer Center, New York, US	
17:00 - 17:20	Advanced tumors, new frontiers: Promising results?	
	<u>N. Girard</u> , Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR	
17:20 - 17:30	Q&A	
	A. Speakers, Prague, CZ	

18:15 - 19:45	Medscape Oncology Global - Novel therapies for EGFR exon 20 insertions and ALK-positive NSCLC: Developments and implications Moderation: M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE	South Hall 2
18:15 - 18:20	Welcome and introduction <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
18:20 - 18:35	Precision medicine in NSCLC: From biomarker testing to therapy selection <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	
18:35 - 19:00	Emerging therapies for advanced NSCLC With EGFR Exon 20 insertion mutations: Developments and implications <u>M. Perol</u> , Centre Léon Bérard, Lyon, FR	
19:00 - 19:25	Frontline treatment of ALK-Positive NSCLC: Therapy considerations and selection <u>S. Popat</u> , The Royal Marsden Hospital - NHS Foundation Trust, London, GB	
19:25 - 19:43	Live Q&A / discussion <u>A. Speakers</u> , Prague, CZ	
19:43 - 19:45	Concluding remarks <u>M. Reck</u> , Krankenhaus Grosshansdorf, Grosshansdorf, DE	

18:15 - 19:45	Bristol Myers Squibb - Breaking barriers in thoracic cancers: The expanding possibilities for patients with I-O treatment Moderation: A. Scherpereel, DRC / CHRU of Lille, Lille, FR	Forum Hall
18:15 - 18:18	Welcome & introductions <u>A. Scherpereel</u> , DRC / CHRU of Lille, Lille, FR	
18:18 - 18:25	Is I-O treatment redefining survival for thoracic cancers? <u>A. Scherpereel</u> , DRC / CHRU of Lille, Lille, FR	
18:25 - 18:45	The shifting treatment paradigm with I-O in resectable NSCLC <u>P. Forde</u> , Johns Hopkins University, Baltimore, US	
18:45 - 19:10	Understanding the potential for long-term survival with I-O in metastatic NSCLC <u>N. Reinmuth</u> , Asklepios-Fachklinikum, Gauting, DE	
19:10 - 19:25	Closing remarks & live Q&A <u>A. Scherpereel</u> , DRC / CHRU of Lille, Lille, FR	
19:25 - 19:45	I-O as a new standard for patients with unresectable MPM <u>A. Scherpereel</u> , DRC / CHRU of Lille, Lille, FR	
19:45 - 20:00	Closing remarks & live Q&A <u>A. Scherpereel</u> ¹ , P. Forde ² , N. Reinmuth ³ , ¹ DRC / CHRU of Lille, Lille, FR, ² Johns Hopkins University, Baltimore, US, ³ Asklepios-Fachklinikum, Gauting, DE	

31.03.2022

11:45 - 13:15	How to use real-world evidence for clinical decision making	Club A
----------------------	--	---------------

Club A

Moderation: D. De Ruysscher¹, P. Van Schil², ¹Maastricht Clinic, Maastricht, NL,
²University Hospital Antwerp (UZA), Edegem, BE

11:45 - 12:05 **Real-world data: Methodology**

E. Van De Garde, UMC - University Medical Center Utrecht, Utrecht, NL

12:05 - 12:25 **Relevance of real-world data in thoracic oncology**

S. Ekman, Karolinska University Hospital-Solna, Solna, SE

12:25 - 12:45 **Artificial intelligence to manage large set of data in thoracic oncology**

M. Del Re, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT

12:45 - 13:05 **Deconvolution of big data sets in thoracic oncology**

V. Pancaldi, IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR

13:05 - 13:15 **Q&A**

A. Speakers, Prague, CZ

11:45 - 13:15	ESMO Colloquium supported by Eli Lilly and Co. - One tumour, many faces: Optimising testing, targeting and monitoring oncogene-addicted NSCLC beyond EGFR	Congress Hall
	Moderation: F. Lopez-Rios ¹ , M. Garassino ² , ¹ Hospital Universitario 12 de Octubre, Madrid, ES, ² University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US	
11:45 - 11:55	Introduction	
	<u>M. Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US	
11:55 - 12:15	Tissue testing for actionable biomarkers in patients with advanced NSCLC: Scientific and implementation perspectives and the positioning of molecular tumour boards	
	<u>F. Lopez-Rios</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
12:15 - 12:35	An overview of molecular epidemiology of rare molecular aberrations and matching treatment strategies for patients with non-EGFR, oncogene-addicted advanced NSCLC	
	<u>F. Barlesi</u> , Gustave Roussy - Cancer Campus, Villejuif, FR	
12:35 - 12:55	RET-fused NSCLC: State of the art treatment of advanced disease, including sanctuary sites	
	<u>M. Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US	
12:55 - 13:10	Live Q&A / discussion	
	A. Speakers, Prague, CZ	
13:10 - 13:15	Concluding remarks	
	<u>F. Lopez-Rios</u> , Hospital Universitario 12 de Octubre, Madrid, ES	

11:45 - 13:15	More targets, more drugs, more choices, more conflicts	South Hall 2
	Moderation: K. Kerr ¹ , P. Garrido Lopez ² , ¹ Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB, ² Hospital Universitario Ramon y Cajal, Madrid, ES	
11:45 - 11:55	Case presentation - A patient with ALK+ NSCLC: How clinical characteristics, biopsy specimen and cfDNA can guide treatment decisions	
	<u>L. Mezquita</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
11:55 - 12:10	Integrated testing: The challenges we now face	
	<u>K. Kerr</u> , Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB	
12:10 - 12:25	Targeted therapy and immunotherapy: Can the patient have both?	
	<u>A.-M. Dingemans</u> , Erasmus MC - University Medical Center, Rotterdam, NL	
12:25 - 12:40	Co-mutations: Impact on current treatments and new combinations	
	<u>P. Garrido Lopez</u> , Hospital Universitario Ramon y Cajal, Madrid, ES	
12:40 - 12:55	Rebiopsy and cfDNA in a complex and changing landscape	
	<u>N. Normanno</u> , Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT	
12:55 - 13:15	Discussion	
	A. Speakers, Prague, CZ	
11:45 - 12:45	Surgery vs radiation therapy for stage III NSCLC in the context of immunotherapy	Forum Hall
	Moderation: K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE	
11:45 - 11:55	Introduction and first vote	
	<u>K. Oselin</u> , North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE	
11:55 - 12:15	Surgical perspective on neoadjuvant immunotherapy for resectable stage III non-small cell lung cancer	
	<u>A. Brunelli</u> , St. James's University Hospital, Leeds, GB	
12:15 - 12:35	Radiotherapy perspective for resectable stage III non-small cell lung cancer in the era of immunotherapy	
	<u>C. Faivre-Finn</u> , The Christie NHS Foundation Trust, Manchester, GB	
12:35 - 12:45	Second vote and conclusions	
	<u>K. Oselin</u> , North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE	

13:30 - 15:00	Janssen Pharmaceutica - Evolving treatment options and practices in EGFR-mutant NSCLC	Forum Hall
	Moderation: A. Passaro ¹ , E. Felip ² , ¹ Milan, IT, ² Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, ES	
13:30 - 13:35	Welcome and introductions	
	<u>A. Passaro</u> ¹ , E. Felip ² , ¹ Milan, IT, ² Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, ES	
13:35 - 13:50	Unmet needs in the management of EGFR+ NSCLC	
	<u>N. Leighl</u> ¹ , B. Besse ² , ¹ UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA, ² Institut Gustave Roussy, Villejuif, FR	
13:50 - 14:00	Discussion - Unmet needs in the management of EGFR+ NSCLC	
	<u>B. Besse</u> ¹ , N. Leighl ² , ¹ Institut Gustave Roussy, Villejuif, FR, ² UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
14:00 - 14:15	Advances in the treatment of patients with EGFR exon20ins+ NSCLC	
	<u>T.S.K. Mok</u> ¹ , A. Minchom ² , ¹ Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK, ² London, GB	
14:15 - 14:25	Discussion - Advances in the treatment of patients with EGFR exon20ins+ NSCLC	
	<u>A. Minchom</u> ¹ , T. Mok ² , ¹ London, GB, ² Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK	
14:25 - 14:55	Live Q&A	
	<u>E. Felip</u> ¹ , A. Passaro ² , ¹ Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, ES, ² Milan, IT	
14:55 - 15:00	Key learnings and closing remarks	
	<u>A. Passaro</u> ¹ , E. Felip ² , ¹ Milan, IT, ² Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, ES	

13:30 - 15:00	AstraZeneca - CNS disease management in EGFRm NSCLC Moderation: T.B. Announced, , US	South Hall 2
13:30 - 13:35	Welcome and introduction <u>D. Planchard</u> , Institut Gustave Roussy, Villejuif, FR	
13:35 - 13:50	Current management of CNS disease on EGFRm NSCLC: Medical oncology perspective <u>Å. Helland</u> , Oslo University Hospital, Oslo, NO	
13:50 - 14:05	Addressing CNS relapse risk in early stage EGFRm NSCLC <u>S. Ekman</u> , Karolinska University Hospital-Solna, Solna, SE	
14:05 - 14:20	Current management of CNS disease on EGFRm NSCLC: Radiation oncology perspective <u>S. Combs</u> , -, Munich, DE	
14:20 - 14:40	The future of CNS disease management in EGFRm NSCLC: Panel discussion <u>A. Speakers</u> , Prague, CZ	
14:40 - 15:00	Live audience Q&A and meeting close <u>D. Planchard</u> , Institut Gustave Roussy, Villejuif, FR	
15:15 - 16:45	Minimal residual disease, biological disease Moderation: C. Rolfo, New York, US	South Hall 2
15:15 - 15:35	How to assess MRD in NSCLC? <u>C. Rolfo</u> , New York, US	
15:35 - 15:55	How MRD correlates with imaging in NSCLC? <u>F. Grossi</u> , University of Insubria, Busto Arsizio, IT	
15:55 - 16:15	MRD as a predictor of survival in NSCLC <u>P. Hofman</u> , CHU Nice - Hopital Pasteur, Nice, FR	
16:15 - 16:35	How to design clinical trials integrating MRD? <u>S. Gadgeel</u> , Henry Ford Cancer Institute - Henry Ford Hospital, Detroit, US	
16:35 - 16:45	Q&A A. Speakers, Prague, CZ	

15:15 - 16:45	First line in non-oncogene addicted	Forum Hall
	Moderation: J. Feliciano ¹ , N. Girard ² , ¹ Johns Hopkins Hospital, Baltimore, US, ² Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR	
15:15 - 15:35	Biomarker testing (tissue, blood) for non-oncogenic addicted NSCLC	
	<u>T. Stinchcombe</u> , Duke Cancer Center, Durham, US	
15:35 - 15:55	First line therapy in non-oncogene addicted NSCLC	
	<u>M. Perol</u> , Centre Léon Bérard, Lyon, FR	
15:55 - 16:15	Resistance to therapy in non-oncogene addicted NSCLC	
	<u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
16:15 - 16:35	Long term needs and survivorship needs in advanced NSCLC	
	<u>J. Feliciano</u> , Johns Hopkins Hospital, Baltimore, US	
16:35 - 16:45	Q&A	
	A. Speakers, Prague, CZ	
15:15 - 16:45	Perioperative strategies: ICI, TKIs, adjuvant, neoadjuvant	Club A
	Moderation: J. Remon, HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES	
15:15 - 15:35	Choosing the best endpoints and surrogates for perioperative strategies in NSCLC	
	<u>H. Wakelee</u> , Stanford University School of Medicine/Stanford Cancer Institute, Stanford, US	
15:35 - 15:55	(Neo)Adjuvant TKIs in oncogene addicted tumors	
	<u>P. Forde</u> , Johns Hopkins University, Baltimore, US	
15:55 - 16:15	Opportunities and pitfalls of Adjuvant Immunotherapy in resected NSCLC	
	<u>E. Felip</u> , Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES	
16:15 - 16:35	Opportunities and pitfalls of Neoadjuvant Immunotherapy in resectable NSCLC	
	<u>T. Cascone</u> , The University of Texas M. D. Anderson Cancer Center, Houston, US	
16:35 - 16:45	Q&A	
	A. Speakers, Prague, CZ	
15:15 - 16:35	Proffered Paper session	Congress Hall
	Moderation: L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL	

15:15 - 15:25	<p>10 - Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study (FURLONG)</p> <p><u>Y.-K. Shi</u>¹, G. Chen², X. Wang³, Y. Liu⁴, L. Wu⁵, Y. Hao⁶, C. Liu⁷, S. Zhu⁸, X. Zhang⁹, Y. Li¹⁰, J. Liu¹¹, L. Cao¹², Y. Cheng¹³, H. Zhao¹⁴, S. Zhang¹⁵, A. Zang¹⁶, J. Cui¹⁷, J. Feng¹⁸, F. Liu¹⁹, C. Gu¹⁹, ¹Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center and National Clinical Research Center for Cancer and Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²Harbin Medical University Cancer Hospital, Harbin, CN, ³Xuzhou Central Hospital, Xuzhou, CN, ⁴The First Hospital of China Medical University, Shenyang, CN, ⁵Hunan Cancer Hospital (The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University), Changsha, CN, ⁶The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, CN, ⁷Cancer Hospital of Xinjiang Medical University, Urumqi, CN, ⁸The Affiliated Hospital of Xuzhou Medical College, Xuzhou, CN, ⁹Nantong Cancer Hospital, Nantong, CN, ¹⁰The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, CN, ¹¹The First Affiliated Hospital of Dalian Medical University, Dalian, CN, ¹²The First Affiliated Hospital of the University of Science and Technology of China, Anhui Provincial Hospital, Hefei, CN, ¹³Jilin Cancer Hospital, Changchun, CN, ¹⁴The Second Hospital of Anhui University, Hefei, CN, ¹⁵Beijing Chest Hospital, Beijing, CN, ¹⁶Affiliated Hospital of Hebei University, Baoding, CN, ¹⁷The First Hospital of Jilin University, Changchun, CN, ¹⁸Affiliated Hospital of Nantong University, Nantong, CN, ¹⁹Shanghai Allist Pharmaceutical Technology, Shanghai, CN</p>
15:25 - 15:40	<p>Invited Discussant of 10</p> <p><u>C. Lovly</u>, Nashville, US</p>
15:40 - 15:50	<p>Q&A</p> <p>A. Speakers, Prague, CZ</p>
15:50 - 16:00	<p>800 - Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIa NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study</p> <p><u>E. Felip</u>¹, N. Altorki², C. Zhou³, E. Vallieres⁴, I. Vynnychenko⁵, A. Akopov⁶, A. Martinez-Marti¹, A. Chella⁷, I. Bondarenko⁸, G. Ursol⁹, E. Levchenko¹⁰, N. Kislov¹¹, R. Liersch¹², R. Belleli¹³, V. McNally¹⁴, E. Bennett¹⁵, B. Gitlitz¹⁵, H. Wakelee¹⁶, ¹Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ²New York-Presbyterian Hospital, Weill Cornell Medicine, New York, US, ³Shanghai Pulmonary Hospital, Shanghai, CN, ⁴Swedish Cancer Institute, Seattle, US, ⁵Regional Municipal Institution Sumy Regional Clinical Oncology Dispensary, Sumy State University, Sumy, UA, ⁶Pavlov State Medical University, Saint-Petersburg, RU, ⁷Pneumology Unit, Azienda Ospedaliero Universitaria Pisana, Pisa, IT, ⁸Dnipro State Medical University, Dnipro, UA, ⁹Acinus, Kropyvnytskyi, UA, ¹⁰N.N. Petrov National Medical Research Center of Oncology, St. Petersburg, RU, ¹¹Regional Clinical Oncology Hospital, Yaroslavl, RU, ¹²Clemenshospital Münster, Münster, DE, ¹³F. Hoffmann-La Roche Ltd, Basel, CH, ¹⁴Roche Products Ltd, Welwyn Garden City, GB, ¹⁵Genentech Inc, South San Francisco, US, ¹⁶Stanford University School of Medicine/Stanford Cancer Institute, Stanford, US</p>

16:00 - 16:10	141O - Durvalumab (D) ± tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study <u>N. Reinmuth</u> ¹ , J. Goldman ² , M. Garassino ³ , Y. Chen ⁴ , K. Hotta ⁵ , A. Poltoratskiy ⁶ , D. Trukhin ⁷ , M. Hochmair ⁸ , J.H. Ji ⁹ , M. Özgüroglu ¹⁰ , G. Statsenko ¹¹ , O. Voitko ¹² , N. Conev ¹³ , I. Bondarenko ¹⁴ , H. Mann ¹⁵ , M. Xie ¹⁶ , Y. Shrestha ¹⁷ , P. Chugh ¹⁶ , T. Dalvi ¹⁷ , L. Paz-Ares ¹⁸ , ¹ Asklepios-Fachklinikum, Gauting, DE, ² David Geffen School of Medicine at UCLA, Los Angeles, US, ³ University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ⁴ Cancer & Hematology Centers of Western Michigan, Grand Rapids, US, ⁵ Okayama University Hospital, Okayama, JP, ⁶ Petrov Research Institute of Oncology, St Petersburg, RU, ⁷ Odessa Regional Oncological Dispensary, Odessa, UA, ⁸ Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, ⁹ Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, KR, ¹⁰ Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, TR, ¹¹ Omsk Regional Cancer Center, Omsk, RU, ¹² Kyiv City Clinical Oncological Centre, Kiev, UA, ¹³ Clinic of Medical Oncology, UMHAT St Marina, Varna, BG, ¹⁴ Dnipro State Medical University, Dnipro, UA, ¹⁵ AstraZeneca, Cambridge, GB, ¹⁶ AstraZeneca, Waltham, US, ¹⁷ AstraZeneca, Gaithersburg, US, ¹⁸ Hospital Universitario 12 de Octubre, Madrid, ES	
16:10 - 16:25	Invited Discussant of 80O and 141O <u>F. Cappuzzo</u> , IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT	
16:25 - 16:35	Q&A A. Speakers, Prague, CZ	
17:00 - 18:00	Salvage surgery and RT Moderation: L. Hendriks, Maastricht, NL	Congress Hall
17:00 - 17:15	Case presentation <u>C. Le Pechoux</u> , Institut Gustave Roussy, Villejuif, FR	
17:15 - 17:30	Surgery <u>P. Van Schil</u> , University Hospital Antwerp (UZA), Edegem, BE	
17:30 - 17:45	Radiotherapy <u>D. De Ruysscher</u> , Maastricht Clinic, Maastricht, NL	
17:45 - 18:00	Discussion A. Speakers, Prague, CZ	

17:00 - 18:00	New TNM classification: Anatomical vs biological Moderation: V. Rusch, Memorial Sloan Kettering Cancer Center, New York, US	Forum Hall
17:00 - 17:10	Introduction and first vote <u>V. Rusch</u> , Memorial Sloan Kettering Cancer Center, New York, US	
17:10 - 17:30	Anatomical TNM <u>R. Rami-Porta</u> , Hospital Mutua de Terrassa, Terrassa, ES	
17:30 - 17:50	Biological TNM <u>R. Osarogiagbon</u> , Baptist Cancer Center, Memphis, US	
17:50 - 18:00	Second vote and conclusions <u>V. Rusch</u> , Memorial Sloan Kettering Cancer Center, New York, US	
17:00 - 18:00	Sublobar resection versus lobectomy Moderation: E. Lim, Royal Brompton Hospital, London, GB	Club A
17:00 - 17:10	Introduction and first vote <u>E. Lim</u> , Royal Brompton Hospital, London, GB	
17:10 - 17:30	Sublobar <u>G. Cardillo</u> , Rome, IT	
17:30 - 17:50	Lobectomy <u>A. Verhagen</u> , Radboud University Medical Center, Nijmegen, NL	
17:50 - 18:00	Second vote and conclusions <u>E. Lim</u> , Royal Brompton Hospital, London, GB	
17:00 - 18:00	Mini Oral session 1 Moderation: L. Backhus ¹ , K. Kerr ² , A. Brunelli ³ , ¹ Stanford University, Stanford, US, ² Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB, ³ St. James's University Hospital, Leeds, GB	South Hall 2
17:00 - 17:05	131MO - Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: analysis of vital registration data from the WHO Mortality Database between 2000 and 2017 <u>P. Baum</u> ¹ , H. Winter ² , M. Eichhorn ³ , J. Lenzi ⁴ , ¹ Thoraxklinik Heidelberg GmbH, Heidelberg, DE, ² Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, ³ Thoraxklinik Heidelberg, Heidelberg, DE, ⁴ University of Bologna, Bologna, IT	
17:05 - 17:10	81MO - Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated Results	

C. Lyu¹, W. Fang², W. Jiao³, H. Ma⁴, J. Wang¹, S. Xu⁵, N. Wu¹, R. Wang⁶, Y. Yang⁷, ¹Beijing Cancer Hospital, Beijing, CN, ²Shanghai Chest Hospital, Shanghai, CN, ³Affiliated Hospital of Qingdao University, Qingdao, CN, ⁴The First Affiliated Hospital of Soochow University, Soochow, CN, ⁵Harbin Medical University Cancer Hospital, Harbin, CN, ⁶The Fourth Hospital of Hebei Medical University, Shijiazhuang, CN, ⁷Peking University Cancer Hospital and Institute, Beijing, CN

17:10 - 17:15 **108MO - Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6)**

M. Garassino¹, J. Mazieres², M. Reck³, C. Chouaid⁴, H. Bischoff⁵, N. Reinmuth⁶, L. Cove-Smith⁷, T. Mansy⁸, D. Cortinovis⁹, M.R. Migliorino¹⁰, A. Delmonte¹¹, J. Garcia Sánchez¹², L.E. Chara Velarde¹³, R. Bernabe¹⁴, L. Paz-Ares¹⁵, I. Diaz Perez¹⁶, N. Trunova¹⁶, K. Foroutanpour¹⁶, C. Faivre-Finn¹⁷, ¹University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ²Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR, ³Krankenhaus Grosshansdorf, Grosshansdorf, DE, ⁴Centre Hospitalier Intercommunal de Créteil, Creteil, FR, ⁵Thoraxklinik Heidelberg, Heidelberg, DE, ⁶Asklepios-Fachklinikum, Gauting, DE, ⁷The Christie NHS Foundation Trust and Manchester University Hospitals Foundation Trust, Manchester, GB, ⁸South Tees Hospitals NHS Foundation Trust, Middlesbrough, GB, ⁹ASST-Monza, San Gerardo Hospital, Monza-Brianza, IT, ¹⁰San Camillo-Forlanini Hospital, Rome, IT, ¹¹Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" IRCCS, Meldola, IT, ¹²Hospital Arnau de Vilanova, Fundación para el Fomento de la Investigación Sanitaria i Biomédica de la Comunidad Valenciana (FISABIO), Valencia, ES, ¹³Hospital Universitario de Guadalajara, Guadalajara, ES, ¹⁴Hospital Universitario Virgen del Rocio, Seville, ES, ¹⁵Hospital Universitario 12 de Octubre, Madrid, ES, ¹⁶AstraZeneca, Gaithersburg, US, ¹⁷The University of Manchester and The Christie NHS Foundation Trust, Manchester, GB

17:15 - 17:23 **Invited Discussant of 131MO, 81MO and 108MO**

L. Backhus, Stanford University, Stanford, US

17:23 - 17:28 **82MO - Risk-adjusted mortality rates as a quality proxy outperform volume in lung cancer surgery - a new perspective on hospital centralization using national population-based data**

P. Baum¹, J. Lenzi², C. Rust³, M. Eichhorn⁴, J. Diers⁵, C.-T. Germer⁵, H. Winter⁶, A. Wiegering⁵, ¹Thoraxklinik Heidelberg GmbH, Heidelberg, DE, ²University of Bologna, Bologna, IT, ³Vienna University of Economics and Business, Vienna, AT, ⁴Thoraxklinik Heidelberg, Heidelberg, DE, ⁵University Hospital Wuerzburg, Wuerzburg, DE, ⁶Thoraxklinik Heidelberg gGmbH, Heidelberg, DE

17:28 - 17:33 **109MO - Respect the Middle Lobe: Perioperative Survival of Bilobectomy Compared to Lobectomy and Pneumonectomy**

A. Li¹, M. Canavan¹, T. Ermer¹, M. Kaminski², R. Maduka¹, P. Zhan¹, K. Flores², D. Boffa¹, J. Blasberg¹, ¹Yale School of Medicine, New Haven, US, ²Yale University, New Haven, US

17:33 - 17:39 **Invited Discussant of 82MO and 109MO**

A. Brunelli, St. James's University Hospital, Leeds, GB

- 17:39 - 17:44 **157MO - Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoimmunotherapy**
- M. Casarrubios¹, A. Cruz-Bermudez¹, B. Sierra-Rodero¹, E. Nadal², M.A. Insa Molla³, M.R. Garcia Campelo⁴, C. Garcia Benito⁵, M. Domine Gomez⁶, M. Majem Tarruella⁷, D. Rodriguez Abreu⁸, A. Martinez⁹, J. De Castro Carpeno¹⁰, M. Cobo Dols¹¹, G. Lopez Vivanco¹², N. Vinolas Segarra¹³, I.C. Barneto Aranda¹⁴, S. Viteri¹⁵, B. Massuti Sureda¹⁶, M. Provencio Pulla¹⁷, ¹Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Puerta de Hierro-Majadahonda, Majadahonda, ES, ²ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, ES, ³Hospital Clinico Universitario de Valencia, Valencia, ES, ⁴University Hospital A Coruña, CHUAC, A Coruña, ES, ⁵Hospital Universitario Alvaro Cunqueiro, Vigo, ES, ⁶IIS-Hospital Fundacion Jimenez Diaz, Madrid, ES, ⁷Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ⁸Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, ES, ⁹Vall d'Hebron University Hospital, Barcelona, ES, ¹⁰Hospital Universitario La Paz, Madrid, ES, ¹¹Biomedical Research Institute of Málaga (IBIMA), Malaga, ES, ¹²Hospital de Cruces, Barakaldo, ES, ¹³Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹⁴Hospital Universitario Reina Sofía, Cordoba, ES, ¹⁵UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, ES, ¹⁶Hospital General Universitario de Alicante, Alicante, ES, ¹⁷University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES
- 17:44 - 17:49 **172MO - Analysis of comutations in DNA damage repair (DDR) related pathways with immunotherapeutic biomarkers in Chinese lung cancer patients**
- J. Li¹, J. Xu², C. Xia², P. Luo², S. Ding², ¹Shandong Provincial Hospital, Shandong, CN, ²Shanghai Topgen Biomedical Technology, Shanghai, CN
- 17:49 - 17:55 **Invited Discussant of 157MO and 172MO**
- K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB
- 17:55 - 18:00 **Q&A**
- A. Speakers, Prague, CZ

18:15 - 19:45	Novartis - Management of patients with oncogene-driven NSCLC: The shift towards personalized medicine	Forum Hall
	Moderation: S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
18:15 - 18:18	Welcome and introduction	
	<u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
18:18 - 18:38	Comprehensive biomarker testing: Understanding the person's perspective	
	<u>A.-M. Baird</u> , Dublin, IE	
18:38 - 18:58	Know your options: Biomarker testing as the foundation for treatment selection	
	<u>R. Büttner</u> , Cologne, DE	
18:58 - 19:13	Emerging landscape in biomarkers	
	<u>N. Reguart Aransay</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
19:13 - 19:33	Integration: How can we bring the future forward?	
	<u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
19:33 - 19:43	Q&A with the audience	
	<u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
19:43 - 19:45	Meeting closure	
	<u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	

18:15 - 19:45	Thermo Fisher Scientific - Enabling future improvements in cancer care with fast next -generation sequencing (NGS) results	South Hall 2
	Moderation: N. Normanno, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT	
18:15 - 18:35	Introduction by Chair <u>N. Normanno</u> , Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT	
18:35 - 18:40	Introduction <u>N. Normanno</u> , Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT	
18:40 - 19:00	Complex biomarker driven therapy landscape in NSCLC and latest guidelines <u>F. Cappuzzo</u> , IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT	
19:00 - 19:20	Molecular pathology - Meeting the challenges of a rapidly evolving biomarker landscape <u>J. Beasley</u> , Birmingham, GB	
19:20 - 19:40	Removing barriers to routine NGS testing <u>P. Hofman</u> , CHU Nice - Hopital Pasteur, Nice, FR	
19:40 - 20:00	Case studies and panel discussion - Leveraging fast NGS to potentially improve patient outcomes Y. Wallis ¹ , P. Hofman ² , <u>N. Normanno</u> ³ , F. Cappuzzo ⁴ , ¹ Birmingham, GB, ² CHU Nice - Hopital Pasteur, Nice, FR, ³ Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT, ⁴ Rome, IT	
20:00 - 20:30	Audience Q&A <u>N. Normanno</u> , Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT	

01.04.2022

12:10 - 12:40 Lung cancer in 2030 Congress Hall

12:10 - 12:15 **Introduction**

S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

12:15 - 12:40 **Lung cancer in 2030**

P. Jänne, Dana Farber Cancer Institute, Boston, US

12:45 - 14:15 Novocure - TTFields: A potential innovative treatment modality in lung cancer South Hall 2

Moderation: F. Barlesi¹, L. Petruželka², ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ² Prague, CZ

12:45 - 12:50 **Welcome & objectives**

F. Barlesi¹, L. Petruzelka², ¹Gustave Roussy - Cancer Campus, Villejuif, FR, ² Prague, CZ

12:50 - 13:10 **What are TTFields - Mechanism of action and experiences in solid tumors**

M. Proescholdt, UKR - University Hospital Regensburg, Regensburg, DE

13:10 - 13:30 **TTFields in malignant pleural mesothelioma (MPM) - The STELLAR trial**

G.L. Ceresoli, Humanitas Gavazzeni, Bergamo, IT

13:30 - 13:50 **TTFields: A potential innovative treatment modality in lung cancer - The LUNAR trial and beyond**

M. Cobo Dols, Biomedical Research Institute of Málaga (IBIMA), Malaga, ES

13:50 - 14:15 **Live Q&A / discussion**

L. Petruželka¹, F. Barlesi², A. Speakers¹, ¹ Prague, CZ, ²Gustave Roussy - Cancer Campus, Villejuif, FR

12:45 - 14:15	AstraZeneca - Unresectable stage III NSCLC: No patients left behind	Forum Hall
	Moderation: J. Mazieres, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR	
12:45 - 12:49	Introduction to the faculty and overview of meeting objectives	
	<u>J. Mazieres</u> , Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR	
12:49 - 13:01	Advancements in Radiation Modalities in unresectable stage III NSCLC	
	<u>A.R. Filippi</u> , Fondazione IRCCS Policlinico San Matteo, Pavia, IT	
13:01 - 13:13	Hard to treat patient populations in unresectable stage III NSCLC	
	<u>A. Rimner</u> , Memorial Sloan Kettering Cancer Center, New York, US	
13:13 - 13:28	Case study: Hard-to-treat patient(s) - The need for an MDT approach	
	<u>D. De Ruysscher</u> , Maastrro Clinic, Maastricht, NL	
13:28 - 13:40	Future directions - The treatment paradigm for unresectable Stage III NSCLC	
	<u>S. Formenti</u> , New York, US	
13:40 - 14:05	Live Q&A / discussion	
	<u>A. Speakers</u> , Prague, CZ	
14:30 - 15:00	Value of pathological response as an endpoint	Congress Hall
14:30 - 14:35	Introduction	
	<u>K. Kerr</u> , Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB	
14:35 - 15:00	Value of pathological response as an endpoint	
	<u>W. Travis</u> , New York, US	

15:15 - 16:45	How to tackle synchronous oligometastases	Forum Hall
	Moderation: L. Backhus ¹ , M. Guckenberger ² , ¹ Stanford University, Stanford, US, ² Universitätsspital Zürich, Zürich, CH	
15:15 - 15:35	Surveillance and detection	
	<u>A.D.L. Sihoe</u> , The University of Hong Kong, Hong Kong, CN	
15:35 - 15:55	Role of surgery	
	<u>L. Backhus</u> , Stanford University, Stanford, US	
15:55 - 16:15	Role of radiotherapy	
	<u>S. Senan</u> , Amsterdam UMC - Vrije University Medical Centre (VUmc), Amsterdam, NL	
16:15 - 16:35	Integrative treatment strategies and maintenance therapy	
	<u>S. Padda</u> , Cedars-Sinai Medical Center, Los Angeles, US	
16:35 - 16:45	Q&A	
	A. Speakers, Prague, CZ	
15:15 - 16:45	EGFR, Exon 20 and ALK	Congress Hall
	Moderation: G. Pasello ¹ , T.S.K. Mok ² , ¹ IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ² Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK	
15:15 - 15:35	Molecular mechanisms and approaches to treating resistance to first line osimertinib in EGFR-mutant lung cancer	
	<u>T.S.K. Mok</u> , Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK	
15:35 - 15:55	EGFR exon 20 insertions: Science and emerging therapies	
	<u>A. Addeo</u> , HUG - Hopitaux Universitaires de Geneve, Geneva, CH	
15:55 - 16:15	Other uncommon EGFR mutations: Strategies in management	
	<u>G. Pasello</u> , IOV - Istituto Oncologico Veneto IRCCS, Padova, IT	
16:15 - 16:35	Updates on ALK: TKIs and beyond	
	<u>M.-J. Ahn</u> , Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR	
16:35 - 16:50	Q&A	
	A. Speakers, Prague, CZ	

15:15 - 16:45	Long terms responders	South Hall 2
	Moderation: W. Theelen ¹ , S. Pilotto ² , ¹ Netherlands Cancer Institute, Amsterdam, NL, ² UNIVR - Università di Verona, Verona, IT	

15:15 - 15:35	Oligometastatic NSCLC: Who benefits the most?
	<u>W. Theelen</u> , Netherlands Cancer Institute, Amsterdam, NL

15:35 - 15:55	Long term responders to chemotherapy / antiangiogenics
	<u>S. Pilotto</u> , UNIVR - Università di Verona, Verona, IT

15:55 - 16:15	Long term responders to TKIs in oncogene-addicted NSCLC
	<u>R. Dziadziuszko</u> , Medical University of Gdansk, Gdansk, PL

16:15 - 16:35	Long term responders to immune checkpoint inhibitors
	<u>T. Leal</u> , Emory University, Atlanta, US

16:35 - 16:45	Q&A
	A. Speakers, Prague, CZ

15:15 - 16:45	Living with lung cancer: Meeting unmet needs (LuCE and IASLC Patient Advocacy Committee)	Club A
	Moderation: D. Villalon ¹ , M. Hennink ² , ¹ Barcelona, ES, ² Groningen, NL	
15:15 - 15:25	Lung cancer needs from a psychosocial perspective: A professional's point of view	
	<u>L.D. Csaba</u> , Cluj-Napoca, RO	
15:25 - 15:35	Lung cancer needs from a psychosocial perspective: An advocate's point of view	
	<u>D. Villalon</u> , Barcelona, ES	
15:35 - 15:55	In it for the long term: Dealing with treatment effects	
	<u>M. Hennink</u> , Groningen, NL	
15:55 - 16:15	The impact of lung cancer cachexia	
	<u>M. Muscaritoli</u> , Rome, IT	
16:15 - 16:35	Integration of prehab and rehab in the care pathway	
	<u>G. Sheill</u> , Dublin, IE	
16:35 - 16:45	Q&A/ Discussion	
	A. Speakers, Prague, CZ	

17:00 - 18:30	Covid 19, vaccines and management of patients outside the pandemic	Forum Hall
	Moderation: S. Peters ¹ , H. Wakelee ² , ¹ CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ² Stanford University School of Medicine/Stanford Cancer Institute, Stanford, US	
17:00 - 17:20	Antibody-dependent immune response in cancer patients	
	<u>B. Halmos</u> , Montefiore Medical Center, New York City, US	
17:20 - 17:40	Neutralizing responses in cancer patients and variants	
	<u>M. Obeid</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	
17:40 - 18:00	COVID-19 and cancer, now and later perspectives in US	
	<u>N. Duma</u> , Mayo Clinic, Rochester, US	
18:00 - 18:20	COVID-19 and lung cancer, management outside of the pandemic	
	<u>M. Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US	
18:20 - 18:30	Q&A	
	A. Speakers, Prague, CZ	
17:00 - 18:30	Oncogene addicted tumours, KRAS, RET, HER2, BRAF	Congress Hall
	Moderation: L. Mezquita ¹ , R. Dziadziuszko ² , ¹ Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ² Medical University of Gdansk, Gdansk, PL	
17:00 - 17:20	METex14	
	<u>L. Mezquita</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
17:20 - 17:40	New drugs targeting RET	
	<u>A. Drilon</u> , Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US	
17:40 - 18:00	New drugs targeting HER2	
	<u>J. Mazieres</u> , Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR	
18:00 - 18:20	New drugs targeting BRAF	
	<u>D. Planchard</u> , Institut Gustave Roussy, Villejuif, FR	
18:20 - 18:30	Q&A	
	A. Speakers, Prague, CZ	

17:00 - 18:30	Scientific advances in malignant pleural mesothelioma	South Hall 2
	Moderation: N. Reguart Aransay ¹ , P. Bironzo ² , ¹ Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ² Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT	
17:00 - 17:20	Updates in the biology of malignant mesothelioma	
	<u>P. Bironzo</u> , Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT	
17:20 - 17:40	Surgery for malignant mesothelioma for which patient?	
	<u>I. Opitz</u> , University Hospital Zürich, Zurich, CH	
17:40 - 18:00	Role of radical radiotherapy	
	<u>M. De Perrot</u> , Princess Margaret Cancer Centre, Toronto, CA	
18:00 - 18:20	Systemic treatment: Where are we now and where are we heading?	
	<u>N. Reguart Aransay</u> , Hospital Clinic y Provincial de Barcelona, Barcelona, ES	
18:20 - 18:30	Q&A	
	A. Speakers, Prague, CZ	
17:00 - 18:15	EONS / IASLC Nurses and Allied Health Professionals (NAHP) Committee session 1	Club A
	Moderation: A. Charalambous ¹ , A. O'Meara ² , ¹ Limassol, CY, ² Dublin, IE	
17:00 - 17:20	Survivorship and quality of life through the eyes of the Survivor	
	<u>J. Feldman</u> , Deerfield, US	
17:20 - 17:40	Novel treatments come with novel symptoms	
	<u>A. O'Meara</u> , Dublin, IE	
17:40 - 18:00	A multimodal AI-based toolbox for empowering Imaging Analysis: INCISIVE project	
	<u>A. Charalambous</u> , Limassol, CY	
18:00 - 18:15	Q&A / Discussion	
	A. Speakers, Prague, CZ	

18:45 - 20:15	MSD - Evolving immuno-oncology treatment paradigm in NSCLC	South Hall 2
	Moderation: L. Paz-Ares, Medical Oncology Department - Edificio Maternidad 2ª Planta, Hospital Universitario 12 de Octubre, Madrid, ES	
18:45 - 18:50	Welcome and introduction	
	<u>L. Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
18:50 - 19:00	Current and future treatment modalities for 1L mNSCLC	
	<u>M. Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US	
19:00 - 19:15	Developments in treatment modalities for early-stage NSCLC - Lecture	
	<u>L. Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
19:15 - 19:40	NSCLC patient management based on case studies	
	<u>J. Aerts</u> , Erasmus MC Cancer Institute, Rotterdam, NL	
19:40 - 20:10	Live Q&A	
	<u>M. Garassino</u> ¹ , <u>L. Paz-Ares</u> ² , <u>J. Aerts</u> ³ , ¹ University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ² Hospital Universitario 12 de Octubre, Madrid, ES, ³ Erasmus MC Cancer Institute, Rotterdam, NL	
20:10 - 20:15	Closing remarks	
	<u>L. Paz-Ares</u> , Hospital Universitario 12 de Octubre, Madrid, ES	
18:45 - 19:45	YO Mentorship - How not to get lost in scientific publications: Tips for organized workflow and collaborations	Club A
	Moderation: <u>M. Reck</u> ¹ , <u>A.-M. Dingemans</u> ² , <u>E. Mariamidze</u> ³ , <u>R. Ferrara</u> ⁴ , ¹ Krankenhaus Grosshansdorf, Grosshansdorf, DE, ² Erasmus MC - University Medical Center, Rotterdam, NL, ³ Acad. Fridon Todua Medical Center, Tbilisi, GE, ⁴ Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	
18:45 - 19:45	YO Mentorship - How not to get lost in scientific publications: Tips for organized workflow and collaborations	
	<u>M. Reck</u> ¹ , <u>A.-M. Dingemans</u> ² , <u>E. Mariamidze</u> ³ , <u>R. Ferrara</u> ⁴ , ¹ Krankenhaus Grosshansdorf, Grosshansdorf, DE, ² Erasmus MC - University Medical Center, Rotterdam, NL, ³ Acad. Fridon Todua Medical Center, Tbilisi, GE, ⁴ Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT	

18:45 - 20:15	Sanofi Genzyme - Quantity versus quality of life in advanced NSCLC patients treated with immunotherapy Moderation: T.B. Announced, , US	Forum Hall
18:45 - 18:50	Welcome and introduction <u>D. Gandara</u> , Sacramento, US	
18:50 - 19:10	Defining quality of life and measuring outcomes against goals of therapy <u>D. Gandara</u> , Sacramento, US	
19:10 - 19:30	How has immunotherapy improved quality of life for newly diagnosed patients? <u>Y. Summers</u> , Manchester, GB	
19:30 - 19:50	Ongoing challenges in the care of advanced nondriver NSCLC <u>E. Felip</u> , Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES	
19:50 - 20:15	Live Q&A / discussion <u>A. Speakers</u> , Prague, CZ	
20:00 - 20:45	YO Vesalius talk - Unity through collaboration: Lessons learned and challenges of national and international registries of thoracic cancers Moderation: E. Mariamidze ¹ , S. Pilotto ² , ¹ Acad. Fridon Todua Medical Center, Tbilisi, GE, ² UNIVR - Università di Verona, Verona, IT	Club A
20:00 - 20:00	Live Discussion <u>M. Garassino</u> , University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US	
20:00 - 20:00	Live Discussion <u>S. Peters</u> , CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH	

02.04.2022

13:00 - 14:30	Treatment sequencing after first-line immunotherapy	Forum Hall
	Moderation: F. Cappuzzo ¹ , B. Besse ² , ¹ IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ² Institut Gustave Roussy, Villejuif, FR	

13:00 - 13:20 **Standard of care in immuno-pretreated NSCLC**
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

13:20 - 13:40 **Mechanisms of resistance to immunotherapy**
P. Nisticò, IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT

13:40 - 14:00 **New drugs for immuno-pretreated NSCLC**
M.R. Garcia Campelo, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES

14:00 - 14:20 **Potentiality of CAR-T in lung cancer**
P. Adusumilli, Memorial Sloan Kettering Cancer Center, New York, US

14:20 - 14:30 **Q&A**
A. Speakers, Prague, CZ

13:00 - 14:30	AI-enabled analysis of big data for optimising cancer patient management: A glimpse to the horizon	Congress Hall
	Moderation: A. Scarpa, Ospedale Universitario Verona, Verona, IT	

13:00 - 13:20 **Current practice and emerging breakthroughs in AI empowered pathology and genomics**
A. Scarpa, Ospedale Universitario Verona, Verona, IT

13:20 - 13:40 **Current practice and emerging breakthroughs in AI-imaging/radiomics**
Z. Bodalal, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

13:40 - 14:00 **Current practice and emerging breakthroughs in AI-enabled oncology drug development**
B. Al-Lazikani, Houston, US

14:00 - 14:20 **Man and machine: An uneasy pair in multiparametric decision making?**
N. Paragios, CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR

14:20 - 14:30 **Q&A**
A. Speakers, Prague, CZ

13:00 - 14:00	Oligoprogession in advanced NSCLC	South Hall 2
	Moderation: N. Girard ¹ , L. Hendriks ² , ¹ Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR, ² Maastricht, NL	
13:00 - 13:15	Case presentation: Defining oligoprogession	
	<u>M. Guckenberger</u> , Universitätsspital Zürich, Zürich, CH	
13:15 - 13:30	Is there a role for SBRT in oligoprogession?	
	<u>F. Mcdonald</u> , Royal Marsden Hospital NHS Foundation Trust, London, GB	
13:30 - 13:45	Is there biological rationale for local approaches in oligoprogessive systemic disease?	
	<u>L. Sequist</u> , Massachusetts General Hospital, Boston, US	
13:45 - 14:00	Discussion	
	A. Speakers, Prague, CZ	
13:00 - 14:15	EONS / IASLC Nurses and Allied Health Professionals (NAHP) Committee session 2	Club A
	Moderation: A. Charalambous ¹ , M. Quist ² , ¹ Limassol, CY, ² University hospital Copenhagen, Copenhagen, DK	
13:00 - 13:20	Psycho-support of lung cancer patients and their families at home	
	<u>M. Ftanou</u> , Melbourne, AU	
13:20 - 13:40	Multidisciplinary training in lung cancer professionals: The way forward	
	<u>A. Sajnic</u> , KBC - University Hospital Centre Zagreb, Zagreb, HR	
13:40 - 14:00	The use of non-pharmacological/complementary interventions for the management of oral toxicities in lung cancer	
	<u>C. Cloconi</u> , Nicosia, CY	
14:00 - 14:15	Q&A / Discussion	
	A. Speakers, Prague, CZ	

14:45 - 15:45	Duration of IO: Limited vs forever	Forum Hall
14:45 - 14:55	Introduction and first vote <u>S. Ramalingam</u> , Winship Cancer Institute of Emory University, Atlanta, US	
14:55 - 15:15	Limited <u>B. Besse</u> , Institut Gustave Roussy, Villejuif, FR	
15:15 - 15:35	Forever <u>H. Linardou</u> , Metropolitan Hospital, Athens, GR	
15:35 - 15:45	Second vote and conclusions <u>S. Ramalingam</u> , Winship Cancer Institute of Emory University, Atlanta, US	
14:45 - 16:15	New roads in I-O Moderation: S. Peters ¹ , N. Reguart Aransay ² , ¹ CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ² Hospital Clinic y Provincial de Barcelona, Barcelona, ES	South Hall 2
14:45 - 15:05	A second life for vaccines? <u>L. Bazhenova</u> , Moores Cancer Center - UC San Diego Health, La Jolla, US	
15:05 - 15:25	Playing with checkpoints <u>M. Maio</u> , AOU Senese - Santa Maria delle Scotte, Siena, IT	
15:25 - 15:45	Rethinking cytokines <u>E. Garon</u> , David Geffen School of Medicine at UCLA, Santa Monica, US	
15:45 - 16:05	Personalizing T-cell therapies <u>B. Creelan</u> , H. Lee Moffitt Cancer Center University of South Florida, Tampa, US	
16:05 - 16:15	Q&A A. Speakers, Prague, CZ	

14:45 - 16:15	KRAS: Finally druggable? Moderation: M. Awad, Dana Farber Cancer Institute, Boston, US	Congress Hall
14:45 - 15:05	RAS G12C <u>J. Menis</u> , AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT	
15:05 - 15:25	Acquired resistance to G12C inhibitors: Relevant combination approaches <u>M. Awad</u> , Dana Farber Cancer Institute, Boston, US	
15:25 - 15:45	Combination KRAS with ICI <u>A. Sacher</u> , UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA	
15:45 - 16:05	The end of the beginning: What's next for RAS precision medicine <u>H. Adderley</u> , Manchester, GB	
16:05 - 16:15	Q&A A. Speakers, Prague, CZ	
14:45 - 16:15	From 'subject' to 'participant': Making person centred research a reality (LuCE and IASLC Patient Advocacy Committee) Moderation: A. Curioni ¹ , R.A. Stahel ² , ¹ Zurich, CH, ² Bern, CH	Club A
14:45 - 15:05	Lablife: Going back basics <u>A.-M. Baird</u> , Dublin, IE	
15:05 - 15:25	Translating research from bench to bedside <u>A. Curioni</u> , Zurich, CH	
15:25 - 15:45	Clinical trials to real world environment <u>R.A. Stahel</u> , Bern, CH	
15:45 - 16:05	Patient reported outcomes: Are they currently fit for purpose? <u>J. Galinsky</u> , Edinburgh, GB	
16:05 - 16:15	Q&A / Discussion A. Speakers, Prague, CZ	

16:25 - 16:30	Closing session	Congress Hall
	Moderation: N. Girard ¹ , L. Hendriks ² , ¹ Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR, ² Maastricht University Medical Center (MUMC), Maastricht, NL	

16:25 - 16:30 **Live closing remarks**

N. Girard¹, L. Hendriks², ¹Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR, ²Maastricht University Medical Center (MUMC), Maastricht, NL

03.04.2022

12:00 - 12:45 Poster Display session

Congress Hall

- 12:00 - 12:00 **9P - Final results from TAIL: Updated long-term safety and efficacy of atezolizumab (atezo) in a diverse population of patients (pts) with previously treated advanced NSCLC**
- A. Ardizzoni¹, S. Azevedo², B. Rubio-Viqueira³, D. Rodriguez-Abreu⁴, J. Alatorre-Alexander⁵, H. Smit⁶, J. Yu⁷, K. Syrigos⁸, E. Hoglander⁹, M. Kaul¹⁰, J. Tolson⁹, Y. Hu⁹, H.K. Volla⁹, T. Newsom-Davis¹¹, ¹Division of Medical Oncology, IRCCS Azienda Ospedaliero—Universitaria di Bologna, Bologna, IT, ²Oncology Service, Hospital de Clínicas de Porto Alegre, Porto Alegre, BR, ³Hospital Universitario Quirónsalud Madrid, Madrid, ES, ⁴Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, ES, ⁵Health Pharma Professional Research, Mexico City, MX, ⁶Rijnstate Hospital, Arnhem, NL, ⁷Shandong Cancer Hospital, affiliated to Shandong University, Jinan, Shandong, CN, ⁸National and Kapodistrian University of Athens, Athens, Attica, GR, ⁹F. Hoffmann-La Roche, Ltd, Basel, CH, ¹⁰Genentech, Inc., South San Francisco, US, ¹¹Chelsea and Westminster Hospital, London, GB
- 12:00 - 12:00 **10P - Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO+IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227**
- S. Peters¹, J. Penrod², J. Li², S. Lubinga², R. Gupta², J. Bushong², J. Rizzo², S. Ramalingam³, ¹CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ²Bristol Myers Squibb, Princeton, US, ³Emory, Atlanta, US
- 12:00 - 12:00 **11P - Results of a phase II study investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts**
- M. Krebs¹, M. Majem Tarruella², M. Forster³, J. Peguero⁴, T. Clay⁵, E. Felip⁶, W. Iams⁷, P. Roxburgh⁸, B. Doger De Spéville⁹, P. Bajaj¹⁰, C. Mueller¹¹, F. Triebel¹², ¹Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, GB, ²Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ³UCL Cancer Institute / University College London Hospitals NHS Foundation, London, GB, ⁴Oncology Consultants, Houston, US, ⁵St John of God Subiaco Hospital, Perth, AU, ⁶Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁷Vanderbilt Ingram Cancer Center Division of Hematology/Oncology, Nashville, US, ⁸Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow and Beatson West of Scotland Cancer Centre, Glasgow, GB, ⁹Fundación Jiménez Díaz, Madrid, ES, ¹⁰Tasman Oncology, Queensland, AU, ¹¹Immutep GmbH, Leipzig, DE, ¹²Immutep S.A.S., Orsay, FR
- 12:00 - 12:00 **12P - A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs**
- S.-G. Wu¹, C.-C. Ho², J.C.-H. Yang³, B.-C. Liao¹, C.-Y. Yang², Y.-T. Lin⁴, C.-J. Yu⁵, W.-Y. Liao², J.-Y. Shih⁶, ¹National Taiwan University Hospital Cancer Center, Taipei City, TW, ²National Taiwan University Hospital, Taipei, TW, ³National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, TW, ⁴National Taiwan University

Cancer Center, Taipei, TW, ⁵National Taiwan University Hospital Hsin-Chu Branch, Hsinchu County, TW, ⁶National Taiwan University Hospital, Taipei City, TW

12:00 - 12:00

13P - Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L) osimertinib: An ORCHARD study interim analysis

B.C. Cho¹, M.-J. Ahn², C. Baik³, R. García⁴, J. Goldman⁵, S.-W. Kim⁶, J.S. Lee⁷, M. Nishio⁸, S. Ponce⁹, R. Salgia¹⁰, S. Teraoka¹¹, T. Yoshida¹², H. Yu¹³, H. Ambrose¹⁴, J. Cosaert¹⁴, R. Hartmaier¹⁵, J. Maidment¹⁴, M. Pluta¹⁴, I. Okamoto¹⁶, ¹Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ³University of Washington School of Medicine, Seattle Cancer Care Alliance, Seattle, US, ⁴University Hospital of A Coruña, A Coruña, ES, ⁵David Geffen School of Medicine at UCLA, Los Angeles, US, ⁶Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁷Seoul National University Bundang Hospital, Seongnam, KR, ⁸Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, JP, ⁹Hospital Universitario 12 de Octubre & Centro Nacional de Investigaciones Oncológicas, Madrid, ES, ¹⁰City of Hope National Medical Center, Duarte, US, ¹¹Wakayama Medical University, Wakayama, JP, ¹²The Jikei University Graduate School of Medicine & Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, JP, ¹³Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College, New York, US, ¹⁴AstraZeneca, Cambridge, GB, ¹⁵Translational Medicine, Oncology R&D, Boston, US, ¹⁶Kyushu University, Fukuoka, JP

12:00 - 12:00

14P - Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC): CheckMate 870 long-term results

S. Lu¹, Y. Cheng², J. Zhou³, M. Wang⁴, J. Zhao⁵, B. Wang⁶, G. Chen⁷, J. Feng⁸, Z. Ma⁹, L. Wu¹⁰, C. Wang¹¹, K. Ma¹², S. Zhang¹³, J. Liang¹⁴, Y. Song¹⁵, J. Wang¹⁶, Y.-L. Wu¹⁷, A. Li¹⁸, Y. Huang¹⁹, J. Chang²⁰, ¹Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN, ²Jilin Cancer Hospital, Changchun, CN, ³The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, ⁴Peking Union Medical College Hospital, Beijing, CN, ⁵Peking University Cancer Hospital & Institute, Beijing, CN, ⁶Jinan Military General Hospital, Jinan, CN, ⁷Affiliated Cancer Hospital of Harbin Medical University, Harbin, CN, ⁸Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, Nanjing Medical University Affiliated Cancer Hospital, Nanjing, CN, ⁹Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, CN, ¹⁰Hunan Cancer Hospital (The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University), Changsha, CN, ¹¹Tianjin Medical University Cancer Institute & Hospital, Tianjin, CN, ¹²The First Hospital of Jilin University, Changchun, CN, ¹³Beijing Chest Hospital, Beijing, CN, ¹⁴Peking University International Hospital, Beijing, CN, ¹⁵Nanjing General Hospital, Nanjing, CN, ¹⁶National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN, ¹⁷Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, ¹⁸Bristol Myers Squibb Company, Princeton, US, ¹⁹Bristol-Myers Squibb, Shanghai, CN, ²⁰Shanghai Cancer Center Fudan University, Shanghai, CN

12:00 - 12:00

15P - Preliminary results of histone deacetylase inhibitor tucidinostat combined

with PD-1 inhibitor sintilimab in non-small cell lung cancer failed to standard therapies

Y. Wang¹, G. Yang¹, H. Xu¹, S. Zhang¹, Y. Yang¹, F. Xu¹, S. Lei¹, X. Ai¹, H. Li¹, X. Hao², J. Li², ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN

12:00 - 12:00 **16P - Camrelizumab monotherapy or plus Apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study**

M. Zhao¹, X. Liu², C. Yuan², W. Zheng³, D. Zhang⁴, Q. Long⁵, J. Li⁶, T. Han¹, L. Xu¹, H. Li¹, X. Li¹, S. Shi¹, ¹The First Hospital of China Medical University, Shenyang, CN, ²The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, CN, ³Shengjing Hospital of China Medical University, Shenyang, CN, ⁴Dandong People's Hospital, Dandong, CN, ⁵The Second People's Hospital, Jilin, CN, ⁶China-Japan Union Hospital of Jilin University, Jilin, CN

12:00 - 12:00 **17P - Safety and tolerability of sintilimab (sint) combination therapy in patients with advanced or recurrent non-small cell lung cancer (NSCLC): Pooled safety analysis of ORIENT 11 and ORIENT 12 studies**

G. Gao¹, Y. Zhao², J. Zhou³, B. Li⁴, J. Li⁵, F. Min⁶, Q. Zhu⁷, H. Li⁷, C. Zhou¹, L. Zhang², ¹Shanghai Pulmonary Hospital, Shanghai, CN, ²State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, CN, ³The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, CN, ⁴Beijing Chest Hospital of Beijing Capital Medical University, Beijing, CN, ⁵Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, CN, ⁶Department of Radiation Oncology, Fudan University Shanghai Cancer Center, Shanghai, CN, ⁷Lilly Suzhou Pharmaceutical Co. Ltd, Shanghai, CN

12:00 - 12:00 **18P - RATIONALE-307: Safety analysis of patients (pts) receiving tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone in advanced squamous (sq) NSCLC**

X. Yu¹, J. Wang², Y. Hu³, Y. Sun⁴, J. Zhao⁵, Y. Yu⁶, C. Hu⁷, K. Yang⁸, G. Feng⁹, S.J. Leaw¹⁰, Y. Yuan¹⁰, X. Lin¹¹, F. Bai¹⁰, S. Lu¹², ¹Zhejiang Cancer Hospital, Hangzhou, CN, ²National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN, ³Hubei Cancer Hospital, Wuhan, CN, ⁴Jinan Central Hospital, Shandong, CN, ⁵Peking University Cancer Hospital & Institute, Beijing, CN, ⁶Harbin Medical University Cancer Hospital, Harbin, CN, ⁷The Second Hospital of Central South University, Changsha, CN, ⁸Union Hospital Tongji Medical College Huazhong University of Science and Technology, Hubei, CN, ⁹The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, CN, ¹⁰BeiGene (Shanghai) Co., Ltd., Shanghai, CN, ¹¹BeiGene (Beijing) Co., Ltd., Beijing, CN, ¹²Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN

12:00 - 12:00 **19P - Stable disease (SD) on amivantamab in post-platinum epidermal growth factor receptor (EGFR) Exon 20 insertion (Exon20ins) mutated non-small cell lung cancer (NSCLC): A response-based analysis**

N. Girard¹, K. Park², S. Viteri³, C.A. Schioppa⁴, J. Diels⁴, M. Oguz⁵, B.H. Rodrigues⁶, N.

Rahhali⁷, J. Sermon⁸, F. Ghilotti⁹, T. Li¹⁰, R.E. Knoblauch¹¹, P. Mahadevia¹⁰, B.C. Cho¹²,
¹Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay
 Campus, Versailles, FR, ²Samsung Medical Center, Sungkyunkwan University School of
 Medicine, Seoul, KR, ³UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, ES,
⁴Janssen Pharmaceutica NV, Beerse, BE, ⁵Janssen-Cilag, High Wycombe, GB, ⁶Janssen-
 Cilag, Lagoas Park, PT, ⁷Janssen-Cilag, Issy-les-Moulineaux, FR, ⁸Janssen-Cilag, Beerse,
 BE, ⁹Janssen-Cilag SpA, Cologno Monzese, IT, ¹⁰Janssen R&D, Raritan, US, ¹¹Janssen
 R&D, Spring House, US, ¹²Yonsei Cancer Center, Yonsei University College of Medicine,
 Seoul, KR

- 12:00 - 12:00 **20P - Risk and management of intracranial progression on amivantamab in epidermal growth factor receptor (EGFR) Exon 20 insertion (ex20ins)-mutated non-small cell lung cancer (NSCLC)**
J. Trigo Perez¹, B.C. Cho², K. Park³, N. Girard⁴, S. Viteri⁵, P. Garrido Lopez⁶, M. Krebs⁷,
 M. Thayu⁸, R. Knoblauch⁸, J. Xie⁸, J. Bauml⁸, R. Schnepf⁸, A. Londhe⁸, P. Mahadevia⁹, N.
 Leighl¹⁰, ¹Hospital Universitario Virgen de la Victoria y Regional, IBIMA, Malaga, ES,
²Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ³Samsung
 Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁴Institut Curie,
 Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus,
 Versailles, FR, ⁵UOMI Cancer Center, Clínica Mi Tres Torres, Barcelona, ES, ⁶Hospital
 Universitario Ramon y Cajal, Madrid, ES, ⁷Division of Cancer Sciences, Faculty of
 Biology, Medicine and Health, The University of Manchester and The Christie NHS
 Foundation Trust, Manchester Academic Health Science Centre, Manchester, GB,
⁸Janssen R&D, Spring House, US, ⁹Janssen R&D, Raritan, US, ¹⁰UHN - University Health
 Network - Princess Margaret Cancer Center, Toronto, CA
- 12:00 - 12:00 **21P - Sintilimab in combination with anlotinib in non-small-cell lung cancer patients with uncommon EGFR mutations: A phase II, single-arm, prospective study**
K. Chen¹, Y. Fan², ¹Cancer Hospital of the University of Chinese Academy of Sciences/
 Zhejiang Cancer Hospital, Hangzhou, CN, ²Zhejiang Cancer Hospital, Hangzhou, CN
- 12:00 - 12:00 **22P - EMB-01: An EGFR-cMET bispecific antibody, in advanced/metastatic solid tumors phase I results**
Z. Qing¹, N. Gabrail², D. Uprety³, J. Rotow⁴, B. Han⁵, P. Jänne⁴, M. Nagasaka⁶, M.
 Zheng¹, Y. Zhang⁷, G. Yang⁷, Y. Sun⁷, B. Peng⁷, Y.-L. Wu⁸, ¹Guangdong Lung Cancer
 Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical
 Sciences, Guangzhou, CN, ²Gabrail Cancer Center Research, Canton, US, ³Karmanos
 Cancer Institute, Detroit, US, ⁴Dana- Farber Cancer Institute, Boston, US, ⁵Shanghai
 Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN, ⁶University of
 California Irvine School of Medicine and Chao Family Comprehensive Cancer Center,
 Orange, US, ⁷Shanghai EpimAb Biotherapeutics, Shanghai, CN, ⁸Guangdong Lung
 Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of
 Medical Sciences, Guangzhou, CN
- 12:00 - 12:00 **23P - Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial**
A. Veelen, Maastricht University Medical Center+, Maastricht, NL
- 12:00 - 12:00 **24P - Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and**

safety by line of therapy

F. Griesinger¹, E. Felip², E. Smit³, R. Veillon⁴, J. Raskin⁵, M. Thomas⁶, P. Conte⁷, D. Kowalski⁸, L. Paz-Ares⁹, G. Garcia Ledo¹⁰, F. De Marinis¹¹, A. Scherz¹², K. Berghoff¹³, R. Bruns¹³, G. Otto¹³, P. Paik¹⁴, ¹Pius-Hospital, University Medicine Oldenburg, Oldenburg, DE, ²Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ³Netherlands Cancer Institute, Amsterdam, NL, ⁴CHU Bordeaux, Bordeaux, FR, ⁵Antwerp University Hospital (UZA), Edegem, BE, ⁶Thoraxklinik, University Heidelberg and Translational Lung Research Center Heidelberg (TLRC-H), The German Center for Lung Research (DZL), Heidelberg, DE, ⁷University of Padova and Oncologia Medica 2, Istituto Oncologico Veneto, I.R.C.C.S., Padova, IT, ⁸Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, PL, ⁹Hospital Universitario 12 de Octubre, Madrid, ES, ¹⁰HM CIOCC, Madrid, ES, ¹¹Istituto Europeo di Oncologia IRCCS, Milan, IT, ¹²Inselspital, Bern University Hospital, University of Bern, Bern, CH, ¹³Merck Healthcare KGaA, Darmstadt, DE, ¹⁴Memorial Sloan Kettering Cancer Center, New York, US

12:00 - 12:00 **25P - Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping**

J.C.-H. Yang¹, M.-J. Ahn², H. Sakai³, M. Morise⁴, T. Kato⁵, Y.-M. Chen⁶, J.-Y. Han⁷, J.-J. Yang⁸, J. Zhao⁹, J. Huang¹⁰, K. Berghoff¹⁰, R. Bruns¹⁰, G. Otto¹⁰, X. Le¹¹, P. Paik¹², ¹National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, TW, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ³Saitama Cancer Center, Saitama, JP, ⁴Nagoya University Graduate School of Medicine, Nagoya, JP, ⁵Kanagawa Cancer Center, Yokohama, JP, ⁶Taipei Veterans General Hospital and National Yang-Ming University, Taipei, TW, ⁷The Center for Lung Cancer, National Cancer Center, Goyang, KR, ⁸Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ⁹Peking University Cancer Hospital & Institute, Beijing, CN, ¹⁰Merck Healthcare KGaA, Darmstadt, DE, ¹¹The University of Texas MD Anderson Cancer Center, Houston, US, ¹²Memorial Sloan Kettering Cancer Center, New York, US

12:00 - 12:00 **26P - Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung cancer (aNSCLC): Updated results from GEOMETRY mono-1**

J. Wolf¹, E. Garon², H. Groen³, D. Tan⁴, A. Robeva⁵, S. Le Mouhaer⁶, M. Carhini⁷, A. Yovine⁸, R. Heist⁹, ¹Universitätsklinikum Köln (AöR), Köln, DE, ²David Geffen School of Medicine at UCLA, Santa Monica, US, ³UMCG - University Medical Center Groningen, Groningen, NL, ⁴National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, SG, ⁵Novartis Pharmaceuticals Corporation, East Hanover, US, ⁶Novartis Pharma, Rueil-Malmaison, FR, ⁷Novartis Pharma, Basel, CH, ⁸Oncology DU Global Drug Development, Novartis Pharma AG, Basel, CH, ⁹Massachusetts General Hospital Cancer Center, Boston, US

12:00 - 12:00 **27P - Durability of efficacy and safety with selpercatinib in patients (pts) with RET Fusion+ non-small cell lung cancer (NSCLC)**

A. Drilon¹, V. Subbiah², O. Gautschi³, P. Tomasini⁴, F.G.M. De Braud⁵, B. Solomon⁶, D. Shao-Weng Tan⁷, G. Alonso⁸, J. Wolf⁹, K. Park¹⁰, K. Goto¹¹, V. Soldatenkova¹², S. Szymczak¹², S. Barker¹², T. Puri¹², A. Lin¹², H.H.F. Loong¹³, B. Besse¹⁴, ¹Memorial

Sloan Kettering Evelyn H. Lauder Breast Center, New York, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US, ³Luzerner Kantonsspital, Luzern, CH, ⁴Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁵Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁶Peter MacCallum Cancer Center, Melbourne, AU, ⁷National Cancer Centre Singapore, Singapore, Singapore, SG, ⁸Vall d'Hebron University Hospital, Barcelona, ES, ⁹Universitätsklinikum Köln (AöR), Köln, DE, ¹⁰Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ¹¹National Cancer Center Hospital East, Kashiwa, Chiba, JP, ¹²Eli Lilly and Company, Indianapolis, US, ¹³The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, ¹⁴Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00

28P - Dose determination and pharmacokinetics (PK) of pralsetinib: Results from the phase I ARROW study

J. Gainor¹, M. Taylor², S.-H.I. Ou³, E. Garralda⁴, M. Brose⁵, J. Parepally⁶, H. Zhang⁶, C. Rahal⁶, A. Zalutskaya⁶, V. Subbiah⁷, ¹Massachusetts General Hospital, Boston, US, ²Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, US, ³University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center, Orange, US, ⁴Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Barcelona, ES, ⁵Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, US, ⁶Blueprint Medicines Corporation, Cambridge, US, ⁷The University of Texas M. D. Anderson Cancer Center, Houston, US

12:00 - 12:00

29P - Brigatinib (BRG) vs crizotinib (CRZ) in anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor-naïve ALK+ non-small cell lung cancer (NSCLC): ALTA-1L final results

M. Tiseo¹, S. Popat², H.R. Kim³, M.-J. Ahn⁴, J.C.-H. Yang⁵, J.-Y. Han⁶, M. Hochmair⁷, K. Lee⁸, A. Delmonte⁹, M.R. Garcia Campelo¹⁰, D.-W. Kim¹¹, F. Griesinger¹², E. Felip¹³, R. Califano¹⁴, A. Spira¹⁵, S. Gettinger¹⁶, H. Lin¹⁷, Y. Liu¹⁷, F. Vranceanu¹⁷, D. Camidge¹⁸, ¹Azienda Ospedaliero-Universitaria di Parma, Parma, IT, ²The Royal Marsden Hospital - NHS Foundation Trust, London, GB, ³Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ⁴Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ⁵National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, TW, ⁶The Center for Lung Cancer, National Cancer Center, Goyang, KR, ⁷Karl Landsteiner Institute of Lung Research and Pulmonary Oncology, Klinik Floridsdorf, Vienna, AT, ⁸Chungbuk National University Hospital, Cheongju, KR, ⁹Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" IRCCS, Meldola, IT, ¹⁰University Hospital A Coruña, CHUAC, A Coruña, ES, ¹¹Seoul National University Hospital, Seoul, KR, ¹²Pius-Hospital, University Medicine Oldenburg, Oldenburg, DE, ¹³Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ¹⁴The Christie NHS Foundation Trust, Manchester, GB, ¹⁵Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, US, ¹⁶Yale Cancer Center, New Haven, US, ¹⁷Takeda Development Center Americas, Inc., Lexington, US, ¹⁸University of Colorado Cancer Center, Aurora, US

12:00 - 12:00

30P - A phase I, dose-escalation and dose-expansion study of SY-3505: A third-generation ALK TKI in Chinese ALK positive advanced non-small cell lung cancer

Y.-K. Shi¹, X. Hu¹, X. Li², Y. Li³, L. Jiang⁴, S. Zhang⁵, H. Wang⁶, Y. Sun⁷, ¹Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer

Center and National Clinical Research Center for Cancer and Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²The First Affiliated Hospital of Zhengzhou University, Zhengzhou, CN, ³Chongqing University Cancer Hospital, Chongqing, CN, ⁴Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ⁵Beijing Chest Hospital, Beijing, CN, ⁶Henan Cancer Hospital/Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, CN, ⁷Shouyao Holdings (Beijing) Co., Ltd, Beijing, CN

- 12:00 - 12:00 **31P - Efficacy and safety of utidelone in treatment-refractory advanced non-small cell lung cancer**
- Y.-K. Shi¹, G. Chen², Y. Zhao³, J. Zhao⁴, L. Lin⁵, ¹Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center and National Clinical Research Center for Cancer and Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ²Harbin Medical University Cancer Hospital, Harbin, CN, ³Henan Provincial Cancer Hospital, Henan, CN, ⁴Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ⁵National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN
- 12:00 - 12:00 **32P - Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC: A systematic review and meta-analysis**
- U. Dafni¹, R. Soo², S. Peters³, Z. Tsourti⁴, K. Vervita⁴, J.-Y. Han⁵, J. De Castro⁶, L. Coate⁷, M. Früh⁸, S. Hashemi⁹, E. Nadal¹⁰, E. Carcereny¹¹, M. Angeles Sala González¹², R. Bernabe Caro¹³, M. Provencio Pulla¹⁴, S. Cuffe¹⁵, B. Ruepp¹⁶, H. Roschitzki-Voser¹⁶, R. Rosell¹⁷, R.A. Stahel¹⁸, ¹National and Kapodistrian University & Frontier Science Foundation Hellas, Athens, GR, ²National University Cancer Institute, Singapore, SG, ³CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ⁴Frontier Science Foundation Hellas, Athens, GR, ⁵The Center for Lung Cancer, National Cancer Center, Goyang, KR, ⁶Hospital Universitario La Paz, Madrid, ES, ⁷University Hospital Limerick, Limerick, IE, ⁸Cantonal Hospital St. Gallen, St.Gallen, CH, ⁹Amsterdam UMC, VU University Medical Center, Amsterdam, NL, ¹⁰ICO L'Hospitalet, Barcelona, ES, ¹¹ICO - Institut Català d'Oncologia Badalona, Badalona, ES, ¹²Hospital Universitario Basurto, Bilbao, ES, ¹³Hospital Universitario Virgen del Rocío, Sevilla, ES, ¹⁴University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ¹⁵St. James's Hospital, Dublin, IE, ¹⁶European Thoracic Oncology Platform (ETOP), Bern, CH, ¹⁷Catalan Institute of Oncology (ICO), Barcelona, ES, ¹⁸Bern, CH
- 12:00 - 12:00 **33P - A literature review of Stevens-Johnson syndrome (SJS)/ toxic epidermal necrolysis (TEN) caused by immune checkpoint inhibitors (ICIs), epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and multikinase inhibitors (MKIs)**
- Z. Hu¹, H. Dong¹, Y. Zhai², H. Cui¹, C. Li¹, J. Li¹, C. Xue¹, X. Lu¹, Y. Yu¹, ¹China-Japan Friendship Hospital, Beijing, CN, ²Beijing University of Chinese Medicine Dongzhimen Hospital, Beijing, CN
- 12:00 - 12:00 **34P - RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions**

A. Marinello¹, M. Duruisseaux², W.S. Zrafi¹, F.G. Dall'Olio¹, G. Massa³, P. Iranzo⁴, F. Tabbò⁵, F. Guisier⁶, C. Lindsay⁷, V. Fallet⁸, C. Audigier-Valette⁹, L. Mezquita¹⁰, A. Calles¹¹, G. Mountzios¹², M. Tagliamento¹, J. Raimbourg¹³, S. Terrisse¹⁴, D. Planchard¹, B. Besse¹, M. Aldea¹⁵, ¹Institut Gustave Roussy, Villejuif, FR, ²Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, FR, ³Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT, ⁴Vall d'Hebron University Hospital, Barcelona, ES, ⁵Università Degli Studi Di Torino - Orbassano, Orbassano, IT, ⁶Hopital Charles-Nicolle - CHU de Rouen, Rouen, FR, ⁷The Christie NHS Foundation Trust, Manchester, GB, ⁸Hopital Tenon AP-HP, Paris, Cedex, FR, ⁹Hospital Sainte Musse, Toulon, FR, ¹⁰Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹¹Hospital Universitario Gregorio Marañón, Madrid, ES, ¹²Henry Dunant Hospital Centre, Athens, GR, ¹³ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ¹⁴Hopital Saint Louis AP-HP, Paris, FR, ¹⁵Institut Gustave Roussy, Villejuif, Cedex, FR

12:00 - 12:00 **35P - Real-world treatment outcomes of amivantamab in pre-approval access (PAA) participants with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertion mutations (ex20ins)**

T.M. Kim¹, S.-H. Lee², G.-C. Chang³, J.-Y. Shih⁴, M. Hochmair⁵, J. Sabari⁶, A. Spira⁷, C. Schioppa⁸, J. Rose⁹, M. Chioda⁹, A. Panaccione⁹, P. Mahadevia⁹, B.C. Cho¹⁰, ¹Seoul National University Hospital, Seoul, KR, ²Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, KR, ³Chung Shan Medical University Hospital, Taichung City, TW, ⁴National Taiwan University Hospital, Taipei City, TW, ⁵Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Krankenhaus Nord, Vienna, AT, ⁶NYU School of Medicine, New York, US, ⁷Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, US, ⁸Janssen Pharmaceutica NV, Beerse, BE, ⁹Janssen R&D, Raritan, US, ¹⁰Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR

12:00 - 12:00 **36P - Indirect comparison of mobocertinib trial data vs real-world data in patients with EGFR exon 20 insertion (ex20ins)+ non-small cell lung cancer (NSCLC)**

P. Christopoulos¹, T. Prawitz², J.-L. Hong³, H. Lin³, L. Hernandez³, S. Jin³, M. Tan⁴, I. Proskorovsky⁵, J. Lin³, P. Zhang³, J. Patel⁶, S.-H.I. Ou⁷, M. Thomas⁸, A. Stenzinger⁹, ¹Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, ²PPD France, Ivry-sur-Seine, FR, ³Takeda Development Center Americas, Inc., Lexington, US, ⁴Evidera, London, GB, ⁵Evidera, Montreal, CA, ⁶Northwestern University, Chicago, US, ⁷University of California Irvine School of Medicine, Orange, US, ⁸Thoraxklinik, University Heidelberg and Translational Lung Research Center Heidelberg (TLRC-H), The German Center for Lung Research (DZL), Heidelberg, DE, ⁹Institute of Pathology Heidelberg (IPH), University Hospital Heidelberg, Heidelberg, DE

12:00 - 12:00 **37P - Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer**

A. Chour¹, J. Denis¹, C. Lafitte¹, C. Mascaux², M. Zysman³, A. Lemaitre⁴, A. Swalduz⁵, V. Gounant⁶, A. Cortot⁷, M. Darrason⁸, J. Cadranel⁹, E. Auclin¹⁰, C. Basse¹¹, C. Tissot¹², C. Decroisette¹³, P. Bombaron¹⁴, E. Giroux-Leprieur¹⁵, L. Falchero¹⁶, F. Lebossé¹⁷, M. Duruisseaux¹⁸, ¹Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, FR, ²Hopitaux Universitaires de Strasbourg - Nouvel Hopital Civil, Strasbourg, FR, ³Hôpital Haut-Lévêque CHU Bordeaux, Pessac, FR, ⁴CHU Rangueil, Toulouse, FR, ⁵Centre Léon Bérard,

Lyon, FR, ⁶Hopital Bichat Claude Bernard, Paris, FR, ⁷Centre Hospitalier Régional Universitaire de Lille, Lille, FR, ⁸Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ⁹Hopital Tenon AP-HP, Paris, Cedex, FR, ¹⁰HEGP - Hopital Europeen Georges-Pompidou - AP-HP, Paris, FR, ¹¹Institut Curie, Paris, FR, ¹²Institut de Cancérologie de la Loire, Saint-Priest-en-Jarez, FR, ¹³Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, ¹⁴Hôpital privé Jean Mermoz, Lyon, FR, ¹⁵Hopital Ambroise Pare AP-HP, Boulogne-Billancourt, FR, ¹⁶Hospital Center De Villefranche-Sur-Saône, Gleizé, FR, ¹⁷Hôpital de la Croix-Rousse, Lyon, FR, ¹⁸Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, FR

12:00 - 12:00 **38P - The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): Differences between KRAS G12C and non-G12C**

L. Notario Rincon¹, A. Pous¹, A. López-Paradís¹, G. Cerdá¹, M. Cucurull¹, A. Hernández¹, M. Domènech¹, E. Carcereny¹, M.T. Moran Bueno¹, A. Muñoz², J.L. Mate², C. Sanz², M. Saigi¹, ¹ICO - Institut Català d'Oncologia Badalona, Badalona, ES, ²Hospital Germans Trias i Pujol, Badlona, ES

12:00 - 12:00 **39P - Determination of essential biomarkers in lung cancer: A real-world data study in Spain**

V. Calvo De Juan¹, M. Cobo Dols², D. Rodriguez-Abreu³, E. Carcereny⁴, A. Cantero⁵, R. Bernabe Caro⁶, G. Benitez Lopez⁷, R. Lopez Castro⁸, B. Massuti Sureda⁹, E. Del Barco¹⁰, M.R. Garcia Campelo¹¹, M. Guirado¹², C. Camps Herrero¹³, A.L. Ortega Granados¹⁴, J. Gonzalez-Larriba¹⁵, A. Sanchez Hernandez¹⁶, C. Gonzalez Ojea¹⁷, M.A. Sala Gonzalez¹⁸, O.J. Juan Vidal¹⁹, M. Provencio Pulla¹, ¹University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ²Biomedical Research Institute of Málaga (IBIMA), Malaga, ES, ³Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, ES, ⁴ICO - Institut Català d'Oncologia Badalona, Badalona, ES, ⁵Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES, ⁶Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁷Complejo Hospitalario Universitario Insular-Materno Infantil, Las Palmas de Gran Canaria, ES, ⁸Hospital Clinico Universitario De Valladolid, Valladolid, ES, ⁹Hospital General Universitario de Alicante, Alicante, ES, ¹⁰Hosp. Clinico Unversitario Salamanca, Salamanca, ES, ¹¹Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ¹²Hospital General Universitario de Elche, Elche, ES, ¹³Hospital General Universitario Valencia, Valencia, ES, ¹⁴Hospital Universitario de Jaén, Jaén, ES, ¹⁵Hospital Clinico Universitario San Carlos, Madrid, ES, ¹⁶Consorcio Hospitalario Provincial de Castellón, Castellon de la Plana, ES, ¹⁷Hospital Universitario Alvaro Cunqueiro, Vigo, ES, ¹⁸Hospital Universitario de Basurto, Bilbao, ES, ¹⁹Hospital Universitari i Politècnic La Fe, Valencia, ES

12:00 - 12:00 **40P - Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): A real-world analysis**

G. Pretelli¹, A. Pavan², A. Dal Maso³, M.V. Resi¹, C. Mulargiu¹, A. Ferro⁴, B. Benetti¹, M. Lorenzi¹, G.M. Marinato¹, S. Frega⁵, G. Pasello⁶, P.F. Conte¹, V. Guarneri³, L. Bonanno⁵, ¹University of Padua, Padua, IT, ²AULSS 3 Serenissima, Mestre, IT, ³University of Padua, Padova, IT, ⁴Veneto Institute of Oncology IOV - IRCCS, Padua, IT, ⁵Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ⁶IOV - Istituto Oncologico Veneto IRCCS, Padova, IT

- 12:00 - 12:00 **41P - Progression after chemo-IO and durvalumab in stage III non-small cell lung cancer (NSCLC): What should be the next line? Real-world study**
T. Shentzer Kutiel¹, S. Shamai², B. Waissengrin², D. Urban³, S. Daher³, H. Sorotzky³, M. Wollner⁴, A. Zer⁴, J. Bar³, M. Moskovitz⁴, ¹Rambam Medical Center, Haifa, IL, ²Tel Aviv Sourasky Medical Center, Tel Aviv, IL, ³Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, IL, ⁴Rambam Health Care Campus, Hifa, IL
- 12:00 - 12:00 **42P - Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low**
I. Attili¹, C. Valenza¹, C. Santoro¹, G. Antonarelli¹, P. Trillo Aliaga¹, E. Del Signore¹, C. Catania¹, G. Spitaleri¹, A. Passaro², F. De Marinis³, ¹IEO - Istituto Europeo di Oncologia, Milan, IT, ²Milan, IT, ³Istituto Europeo di Oncologia IRCCS, Milan, IT
- 12:00 - 12:00 **43P - Update on long term outcome of a multicentre, prospective, real-world study of camrelizumab in the treatment of patients with advanced lung cancer**
Y. Shu¹, R. Wang², M. Ji³, M. Shi¹, X. Zhang⁴, ¹Jiangsu Province People's Hospital, Nanjing, CN, ²Nanjing University, Nanjing, CN, ³The First People's Hospital of Changzhou, Changzhou, CN, ⁴Subei People's Hospital of Jiangsu province, Yangzhou, CN
- 12:00 - 12:00 **44P - Real-world (RW) treatment patterns, patient characteristics and outcomes in advanced non-small cell lung cancer (aNSCLC) with PD1/L1 as first-line (1L) therapy in the UK and Germany**
M. Snee¹, S. Cheeseman¹, B. Levick¹, G. Hall¹, G. Rohde², J. Stratmann², A. Wolf³, C. Van Gils⁴, R. Griner⁵, A. Mahmood⁶, N. Niklas⁷, H. Divan⁸, A. Krishna⁹, ¹The Leeds Teaching Hospitals NHS Trust, Leeds, GB, ²University Hospital Frankfurt, Frankfurt, DE, ³University Cancer Center, University Hospital Frankfurt, Frankfurt, DE, ⁴IQVIA, Amsterdam, NL, ⁵IQVIA, Deerfield, US, ⁶IQVIA, London, GB, ⁷IQVIA, Frankfurt, DE, ⁸Sanofi Digital, Cambridge, US, ⁹Sanofi, Mumbai, IN
- 12:00 - 12:00 **45P - Pembrolizumab versus best supportive care survival outcomes in ECOG performance status 2 NSCLC patients**
A. Elegbede¹, A. Pabani², A. Gibson¹, W. Cheung³, ¹University of Calgary, Calgary, CA, ²Tom Baker Cancer Center, Calgary AB, CA, ³Oncology Outcomes Research Initiative, University of Calgary, Calgary, CA
- 12:00 - 12:00 **46P - Prognostic impact of immune checkpoint inhibition in patients with metastatic non-small cell lung cancer (NSCLC): Real world study in central Switzerland**
D. Allmann¹, O. Gautschi², D. Lehnick³, D. Dyntar³, C. Schwegler², M. Dressler⁴, J. Godau⁵, P. Niederberger², K. Zeidler², J. Diebold², ¹University of Basel, Basel, CH, ²Luzerner Kantonsspital, Luzern, CH, ³University of Lucerne, Luzern, CH, ⁴Hirslanden Klinik St. Anna, Luzern, CH, ⁵Spital Thun, Thun, CH
- 12:00 - 12:00 **47P - Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small cell lung cancer**
R. Wan¹, J. Duan¹, Z. Wang¹, L. Lin², W. Li¹, W. Jie³, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical

Sciences and Peking Union Medical College, Beijing, CN, ²National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN, ³Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN

- 12:00 - 12:00 **48P - Efficacy of osimertinib (osi) on (prevention of) bone metastases (mets) and skeletal related events (SREs) in patients (pts) with epidermal growth factor receptor mutated (EGFRm+) non-small cell lung cancer (NSCLC)**
- A. Brouns¹, A. Veelen², M. Veerman³, C. Steendam³, S. Dursun⁴, S. Croes², A.-M. Dingemans⁵, L. Hendriks⁶, ¹Zuyderland Medical Center, Heerlen, NL, ²Maastricht University Medical Center+, Maastricht, NL, ³MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, NL, ⁴GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, NL, ⁵Erasmus MC - University Medical Center, Rotterdam, NL, ⁶Maastricht University Medical Center (MUMC), Maastricht, NL
- 12:00 - 12:00 **49P - EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315)**
- F. Griesinger¹, M. Sebastian², A. Bethge³, P. Christopoulos⁴, P. Hoffknecht⁵, C. Waller⁶, R. Benkelmann⁷, M. Jänicke⁸, A. Fleitz⁸, J. Hanselmann⁸, A. Hipper⁹, A. Groth⁹, W. Weichert¹⁰, A. Nusch¹¹, J. Rauh¹², T. Fietz¹³, T. Illmer¹⁴, R. Depenbusch¹⁵, W. Eberhardt¹⁶, M. Thomas¹⁷, ¹Pius-Hospital, University Medicine Oldenburg, Oldenburg, DE, ²Universitätsklinikum Frankfurt (Johannes-Wolfgang Goethe-Universität), Frankfurt am Main, DE, ³Klinikum Bremen-Ost, Bremen, DE, ⁴Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, ⁵Franziskus-Hospital Harderberg - Niels-Stensen-Kliniken GmbH, Georgsmarienhütte, DE, ⁶Universitätsklinikum Freiburg, Freiburg im Breisgau, DE, ⁷Medizinische Klinik-Klinikum Konstanz, Konstanz, DE, ⁸iOMEDICO, Freiburg im Breisgau, DE, ⁹AIO-Studien-gGmbH, Berlin, DE, ¹⁰Technische Universität München, Munich, DE, ¹¹Praxis für Hämatologie und internistische Onkologie, Ratingen, DE, ¹²GIM - Gemeinschaftspraxis, Witten, DE, ¹³Schwerpunktpraxis für Hämatologie und Internistische Onkologie, Gastroenterologie, Singen, DE, ¹⁴BAG / Onkologische Gemeinschaftspraxis, Dresden, DE, ¹⁵Onkologische Schwerpunktpraxis, Gütersloh, DE, ¹⁶University Hospital Essen, Department of Medical Oncology, West German Cancer Center and Ruhrlandklinik, University Duisburg-Essen, Essen, DE, ¹⁷Thoraxklinik, University Heidelberg and Translational Lung Research Center Heidelberg (TLRC-H), The German Center for Lung Research (DZL), Heidelberg, DE
- 12:00 - 12:00 **50P - Clinical characteristics, treatment patterns and outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC patients**
- S. Yoon¹, S.M. Lim², H.A. Jung³, K.-P. Kim⁴, D. Kim⁵, H. Jeong⁴, S. Lim⁵, J. Kim⁶, J. Kim⁶, D. Patel⁷, X. Zhao⁷, D. Horsburgh⁷, D.Y. Yu⁸, J.H. Kim⁸, S.Y. Kim⁸, D.H. Lee⁹, ¹Asan Medical Center - Asan Institute for Life Science, Seoul, US, ²Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ³Division of Hematology-Oncology, Department of Medicine, Seoul, KR, ⁴Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, KR, ⁵Real-World Evidence Team, ALYND, Yonsei University Health System, Seoul, KR, ⁶IQVIA Real-World Solutions Korea, Seoul, KR, ⁷IQVIA Real-World Solutions Asia-Pacific, Singapore, SG, ⁸Medical Affairs, Janssen Korea, Seoul, KR, ⁹Asan Medical Center, Seoul, KR

- 12:00 - 12:00 **51P - Testing patterns and outcomes of different EGFR positive metastatic non-small cell lung cancer (NSCLC) patients in a Canadian real-world setting**
- D. Boyne¹, T. Jarada¹, A. Yusuf¹, D. O'Sullivan¹, L. Hu¹, D. Brenner¹, E. Abbie², J. Rose³, K. Eaton², E. Ewara², W. Cheung¹, ¹Oncology Outcomes Research Initiative, University of Calgary, Calgary, CA, ²Janssen Inc., Toronto, CA, ³Janssen R&D, Raritan, US
- 12:00 - 12:00 **52P - ROS1 aberrations in non-small cell lung cancer patients without rearrangements: Clinical and molecular characteristics**
- M. Glaser¹, C. Von Levetzow¹, S. Michels¹, L. Nogova¹, M. Katzenmeier¹, C. Wömpner¹, J. Schmitz¹, E. Bitter¹, I. Terjung¹, E. Passmann¹, D. Schaufler¹, A. Eisert¹, R. Fischer¹, R. Riedel¹, J.-P. Weber¹, S. Hahne¹, S. Merkelbach-Bruse², R. Büttner³, J. Wolf⁴, M. Scheffler¹, ¹University Hospital Cologne, Köln, DE, ²University of Cologne, Köln, DE, ³Cologne, DE, ⁴Universitätsklinikum Köln (AÖR), Köln, DE
- 12:00 - 12:00 **53P - Second line treatment in advanced non-squamous (NS) non-small cell lung cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)**
- E. Carcereny Costa¹, A. Collazo Lorduy², M. Cobo Dols³, D. Rodriguez Abreu⁴, R. Bernabe Caro⁵, R. Lopez Castro⁶, B. Massuti Sureda⁷, E. Del Barco⁸, M. Guirado⁹, J. Bosch-Barrera¹⁰, J. Gonzalez-Larriba¹¹, A. Sanchez Hernandez¹², O.J. Juan Vidal¹³, J. Oramas Rodriguez¹⁴, J. Mosquera Martinez¹⁵, A.L. Ortega Granados¹⁶, A. Padilla¹⁷, M.T. Moran Bueno¹⁸, A. Cantero¹⁹, M. Provencio Pulla², ¹ICO - Institut Català d'Oncologia Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES, ²University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES, ³Biomedical Research Institute of Málaga (IBIMA), Malaga, ES, ⁴Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, ES, ⁵Hospital Universitario Virgen del Rocío, Sevilla, ES, ⁶Hospital Clinico Universitario De Valladolid, Valladolid, ES, ⁷Hospital General Universitario de Alicante, Alicante, ES, ⁸Hosp. Clinico Unversitario Salamanca, Salamanca, ES, ⁹Hospital General Universitario de Elche, Elche, ES, ¹⁰ICO Girona - Institut Català d'Oncologia Girona, Girona, ES, ¹¹Hospital Clinico Universitario San Carlos, Madrid, ES, ¹²Consortio Hospitalario Provincial de Castellón, Castellon de la Plana, ES, ¹³Hospital Universitari i Politècnic La Fe, Valencia, ES, ¹⁴Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ¹⁵CHUAC - Complejo Hospitalario Universitario A Coruña, A Coruña, ES, ¹⁶Hospital Universitario de Jaén, Jaén, ES, ¹⁷Hospital Universitario Nuestra Señora de Candelaria, Santa Cruz de Tenerife, ES, ¹⁸ICO - Institut Català d'Oncologia Badalona, Badalona, ES, ¹⁹Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES
- 12:00 - 12:00 **54P - Overall survival in patients with metastatic lung cancer from 2000 to 2020: Implementation of innovative strategies in a real-world setting**
- C. Basse¹, M. Carton¹, M. Milder², S. Beaucaire Danel¹, C. Daniel¹, P. Du Rusquec¹, A. Livartowski¹, N. Girard³, ¹Institut Curie, Paris, FR, ²Institut Curie, PARIS, FR, ³Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR
- 12:00 - 12:00 **55P - The impact of liquid next-generation testing timing on treatment-**

naïve advanced non-small cell lung cancer: A prospective observational study

C. Yang¹, W.-Y. Liao², C.-C. Ho², C.-L. Hsu¹, T.-H. Tsai¹, S.-G. Wu³, Y.-T. Lin⁴, W.-H. Hsu², J.C.-H. Yang⁵, C.-J. Yu⁶, P.-C. Yang¹, ¹National Taiwan University Hospital, Taipei City, TW, ²National Taiwan University Hospital, Taipei, TW, ³National Taiwan University Hospital Cancer Center, Taipei City, TW, ⁴National Taiwan University Cancer Center, Taipei, TW, ⁵National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, TW, ⁶National Taiwan University Hospital Hsin-Chu Branch, Hsinchu County, TW

12:00 - 12:00 **56P - Simultaneous tissue and liquid next-generation sequencing after first-line EGFR tyrosine kinase inhibitors resistance in advanced non-small cell lung cancer**

Y.-T. Lin¹, C.-C. Ho², W.-H. Hsu², W.-Y. Liao², C.-Y. Yang², K.T. Tan³, W. Hsiao³, J.-Y. Shih⁴, ¹National Taiwan University Cancer Center, Taipei, TW, ²National Taiwan University Hospital, Taipei, TW, ³ACT Genomics, Taipei, TW, ⁴National Taiwan University Hospital, Taipei City, TW

12:00 - 12:00 **57P - Acquired concurrent EGFR T790M and driver gene resistance from EGFR-TKIs hampered osimertinib efficacy in advanced lung adenocarcinoma**

F. Wu¹, Y. Zeng¹, Y. Feng², G. Fu², J. Jiang³, X. Liu¹, Y. Pan¹, C. Hu⁴, X. Liu¹, ¹The Second Xiangya Hospital of Central South University, Changsha, CN, ²Xiangtan Central Hospital, Xiangtan, CN, ³Jiangnan hospital, Xiangtan, CN, ⁴The Second Hospital of Central South University, Changsha, CN

12:00 - 12:00 **58P - A predictive model of the diagnostic value of next generation sequencing based genomics testing in patients with metastatic non-small cell lung cancer in Spain**

A. Mota¹, A. Molero¹, K. Taipale², A. Gulati³, M.-H. Jen⁴, L. Hess⁵, B. Goel³, ¹Lilly Spain, Madrid, ES, ²Oy Eli Lilly Finland Ab, Helsinki, FI, ³Eli Lilly and Company, Bangalore, IN, ⁴Eli Lilly and Company, Bracknell, GB, ⁵Eli Lilly and Company, Indianapolis, US

12:00 - 12:00 **59P - Clinical utility of plasma cell-free DNA EGFR mutation analysis in treatment-naïve stage IV non-small cell lung cancer patients**

B.-G. Kim, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, KR

12:00 - 12:00 **60P - Machine learning based on blood biomarkers predicts fast progression in advanced NSCLC patients treated with immunotherapy**

J.-G. Zhou¹, J. Yang², H. Wang³, A. Wong⁴, F. Tan⁵, X. Chen⁶, S. He¹, G. Shen¹, Y.-J. Wang¹, B. Frey⁷, R. Fietkau⁷, M. Hecht⁷, H. Ma¹, U. Gaipl⁷, ¹The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, CN, ²Guangdong Provincial People's Hospital, Guangzhou, CN, ³National Cancer Institute/National Institutes of Health, Bethesda, US, ⁴AW Medical Company Limited, Macau SAR, CN, ⁵Harrisburg University of Science & Technology, Harrisburg, US, ⁶Sanofi, New Jersey, US, ⁷Universitätsklinikum Erlangen, Erlangen, DE

12:00 - 12:00 **61P - Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib**

V. Moreno Garcia¹, J. Lin², D. Tan³, U. Lassen⁴, S. Leyvraz⁵, Y. Liu⁶, J. Patel⁷, L. Rosen⁸, B. Solomon⁹, M. Rudolph¹⁰, R. Norenberg¹¹, A. Schulz¹⁰, M. Fellous¹², N. Brega¹³, L. Shen¹⁴, S. Kummar¹⁵, A. Drilon¹⁶, ¹START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, ES, ²Massachusetts General Hospital, Boston, US, ³National Cancer Centre Singapore, Duke-NUS Medical School, Singapore, SG, ⁴Rigshospitalet, Copenhagen, DK, ⁵Charité - Universitätsmedizin Berlin, Berlin, DE, ⁶Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, CN, ⁷Northwestern University, Chicago, US, ⁸UCLA Division of Hematology-Oncology, Los Angeles, US, ⁹Avera Cancer Institute, Sioux Falls, US, ¹⁰Bayer AG Pharmaceuticals, Berlin, DE, ¹¹Chrestos Concept GmbH & Co. KG, Essen, DE, ¹²Bayer HealthCare Pharmaceuticals, Inc., Basel, CH, ¹³Bayer S.p.A., Milan, IT, ¹⁴Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Peking University Cancer Hospital & Institute, Beijing, CN, ¹⁵Oregon Health & Science University, Portland, US, ¹⁶Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

- 12:00 - 12:00 **62P - Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small cell lung cancer patients**
- S. Takamori¹, Y. Oku², G. Toyokawa³, S. Wakasu⁴, F. Kinoshita¹, K. Watanabe², N. Haratake², T. Nagano², K. Kosai², Y. Shiraishi², T. Yamashita², M. Shimokawa⁵, F. Shoji¹, K. Yamazaki⁴, T. Okamoto¹, T. Seto¹, S. Takeo⁴, N. Nakashima², I. Okamoto², T. Takenaka², ¹National Hospital Organization Kyushu Cancer Center, Fukuoka, JP, ²Kyushu University, Fukuoka, JP, ³National Hospital Organization Fukuoka National Hospital, Fukuoka, JP, ⁴Kyushu Medical Center, Fukuoka, JP, ⁵Yamaguchi University, Yamaguchi, JP
- 12:00 - 12:00 **63P - Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): Neutrophil to lymphocyte ratio (NLR) and the risk for toxicity recurrence**
- G. Pretelli¹, A. Pavan², A. Dal Maso³, M.V. Resi¹, C. Mulargiu¹, A. Ferro⁴, B. Benetti¹, M. Lorenzi¹, G.M. Marinato¹, S. Frega⁵, G. Pasello⁶, P.F. Conte¹, V. Guarneri³, L. Bonanno⁵, ¹University of Padua, Padua, IT, ²AULSS 3 Serenissima, Mestre, IT, ³University of Padua, Padova, IT, ⁴Veneto Institute of Oncology IOV - IRCCS, Padua, IT, ⁵Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ⁶IOV - Istituto Oncologico Veneto IRCCS, Padova, IT
- 12:00 - 12:00 **64P - Clinical benefit of platinum doublet therapy for elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the national hospital organization in Japan**
- M. Shimokawa¹, M. Kanazu², R. Saito³, M. Mori⁴, A. Tamura⁵, Y. Okano⁶, Y. Fujita⁷, T. Endo⁸, M. Motegi⁹, S. Takata¹⁰, T. Kita¹¹, N. Sukoh¹², M. Takenoyama¹³, S. Atagi², ¹Yamaguchi University Graduate School of Medicine, Ube, JP, ²Kinki-Chuo Chest Medical Center, Sakai, JP, ³Shibukawa Medical Center, Shibukawa, JP, ⁴Osaka Toneyama Medical Center, Toyonaka, JP, ⁵Tokyo National Hospital, Kiyose, JP, ⁶Kochi Hospital, Kochi, JP, ⁷Asahikawa Medical Center, Asahikawa, JP, ⁸Mito Medical Center, Higashiibaraki, JP, ⁹Takasaki General Medical Center, Takasaki, JP, ¹⁰Fukuokahigashi Medical Center, koga, JP, ¹¹Kanazawa Medical Center, Kanazawa, JP, ¹²Hokkaido Medical Center, sapporo, JP, ¹³Matsuyama Red Cross Hospital, Matsuyama, JP
- 12:00 - 12:00 **65P - Blood cytokine changes in patients with advanced NSCLC receiving immunotherapy**

H. Schindler¹, F. Lusky¹, L. Gaissmaier¹, L. Daniello¹, M. Elshiaty¹, F. Bozorgmehr¹, J. Kuon¹, R. Shah¹, M. Schneider¹, F. Eichhorn¹, P. Baum², A. Angeles³, F. Janke³, M. Kriegsmann⁴, D. Kazdal⁴, A. Stenzinger⁵, H. Sültmann³, M. Thomas⁶, P. Christopoulos¹,
¹Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, ²Thoraxklinik Heidelberg GmbH, Heidelberg, DE, ³DKFZ Heidelberg, Heidelberg, DE, ⁴Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany, Heidelberg, DE, ⁵Institute of Pathology Heidelberg (IPH), University Hospital Heidelberg, Heidelberg, DE, ⁶Thoraxklinik, University Heidelberg and Translational Lung Research Center Heidelberg (TLRC-H), The German Center for Lung Research (DZL), Heidelberg, DE

- 12:00 - 12:00 **66P - Incidence and impact on survival of venous thromboembolic events in patients with advanced non-small cell lung cancer receiving pembrolizumab as first line of treatment**
P. Hulo¹, H. Senellart², T. Chatellier³, J. Bennouna⁴, E. Pons-Tostivint¹, ¹CHU du Nantes - Hôtel-Dieu, Nantes, Cedex, FR, ²ICO Institut de Cancerologie de l'Ouest René Gauducheau, Saint-Herblain, FR, ³Clinique Mutualiste de l'Estuaire, Saint-Nazaire, FR, ⁴Hopital Foch, Suresnes, FR
- 12:00 - 12:00 **67P - Distinct concomitant genetic alterations in EGFR-Mutant non-small cell lung cancer patients with brain metastases**
Y. Fan¹, S. Yu², Y. Xu², Z. Huang², H. Li², K. Chen², L. Gong², X. Xu², ¹Zhejiang Cancer Hospital, Hangzhou, CN, ²Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN
- 12:00 - 12:00 **68P - Clinical implications of cardiotoxicity and pharmacokinetics of alectinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)**
M. Pruis¹, M. Veerman², C. Hassing³, D. Lanser⁴, M. Paats⁵, R. Mathijssen¹, O. Manintveld³, A.-M. Dingemans⁴, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, NL, ³Erasmus MC, Rotterdam, NL, ⁴Erasmus MC - University Medical Center, Rotterdam, NL, ⁵Department of Pulmonary Medicine, Rotterdam, NL
- 12:00 - 12:00 **69P - Tumor invasiveness, response to ALK inhibitors and resistance mechanism in NSCLC with different ALK variants**
Z. Zou, X. Hao, Y. Li, P. Xing, J. Ying, J. Li, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN
- 12:00 - 12:00 **70P - Adherence to treatment recommendations from multidisciplinary tumor boards**
J. Roeper¹, L. Ansmann², L. Kathmann², A. Blanksma², K. Wedeken¹, F. Griesinger³, ¹Pius Hospital, Oldenburg, DE, ²University of Oldenburg, Oldenburg, DE, ³Pius-Hospital, University Medicine Oldenburg, Oldenburg, DE
- 12:00 - 12:00 **71P - Predictors of anxiety and depression among advanced lung cancer patients attending palliative care department: An experience from the rural cancer centre**
C. Patil, P. Tanawade, N. Dhamne, Y. Anap, S. Pawar, Kolhapur Cancer Centre, Kolhapur, IN

- 12:00 - 12:00 **72P - The risk factors of developing severity in immune checkpoint inhibitors-related pneumonitis in advanced lung cancer patients**
Y. Zhang¹, L. Zhang¹, H. Zhong², ¹Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ²Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN
- 12:00 - 12:00 **73P - A novel nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer**
S. Cao, H. Zhong, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN
- 12:00 - 12:00 **74TiP - Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC/IV EGFR-mutant, T790M-negative, MET-amplified NSCLC**
Y.-L. Wu¹, J.-Y. Han², T. Kato³, F. Barlesi⁴, E. Garon⁵, F. Cappuzzo⁶, Y. Shibata⁷, N. Smith⁸, S. Khanna⁹, R. Belli⁸, A. Yovine⁸, D. Shao-Weng Tan¹⁰, ¹Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, ²The Center for Lung Cancer, National Cancer Center, Goyang, KR, ³Kanagawa Cancer Center, Yokohama, JP, ⁴Gustave Roussy - Cancer Campus, Villejuif, FR, ⁵David Geffen School of Medicine at UCLA, Santa Monica, US, ⁶IRCCS Istituto Nazionale Tumori Regina Elena (IRE), Rome, IT, ⁷National Cancer Center Hospital East, Japan, -Tokyo, JP, ⁸Oncology DU Global Drug Development, Novartis Pharma AG, Basel, CH, ⁹Novartis Pharma S.A.S., Paris, FR, ¹⁰National Cancer Centre Singapore, Singapore, Singapore, SG
- 12:00 - 12:00 **75TiP - Open-label, phase II study of tusamitamab ravtansine (SAR408701) in combination with pembrolizumab and with pembrolizumab + platinum-based chemotherapy +/-pemetrexed in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05)**
L. Paz-Ares¹, S. Parakh², J. Park³, C. Rojas⁴, F. Orlandi⁵, R. Veillon⁶, N. Isambert⁷, T. Nagy⁸, V. Müller⁹, B. Medgyasszay¹⁰, D. Rodriguez-Abreu¹¹, A. Fernandez¹², A. Puaud¹³, S. Bensfia¹⁴, N. Yang¹⁵, A. Spira¹⁶, ¹Hospital Universitario 12 de Octubre, Madrid, ES, ²Austin & Repatriation Med. Centre, Heidelberg, AU, ³Macquarie University, Sydney, AU, ⁴Centro de Investigacion Clinica Bradford Hill, Recoleta, CL, ⁵Orlandi Oncologia, Santiago, CL, ⁶CHU Bordeaux, Bordeaux, FR, ⁷CHU La Milétrie, Poitiers, FR, ⁸Országos Onkológiai Intézet, Budapest, HU, ⁹Semmelweis Egyetem Általános Orvostudományi Kar, Pulmonológiai Klinika, Budapest, HU, ¹⁰Veszprém County Lung Hospital, Farkasgyepu, HU, ¹¹Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, ES, ¹²Hospital Quirónsalud Valencia, Valencia, ES, ¹³Sanofi, Chilly-Mazarin, FR, ¹⁴Sanofi, Cambridge, US, ¹⁵Sanofi, Shanghai, CN, ¹⁶Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, US
- 12:00 - 12:00 **76TiP - RMC-4630 and sotorasib for advanced KRASG12C NSCLC after failure of prior standard therapies: A phase II trial**
M. Johnson¹, R. Langdon², D. Ellison³, A. Spira⁴, H. Amin⁵, M. Castine⁶, D. Daniel⁷, S. Sohoni⁸, Y.-C. Chen⁸, J. Hayes⁸, Y. Mu⁸, S. Masciari⁹, X. Wang⁸, S. Toya¹⁰, ¹Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US, ²Nebraska Cancer Specialists,

Omaha, US, ³Charleston Oncology, P.A, Charleston, US, ⁴Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, US, ⁵Boca Raton Clinical Research Associates Inc, Plantation, US, ⁶Hematology Oncology Clinic, Baton Rouge, US, ⁷Sarah Cannon Research Institute at Tennessee Oncology, Chattanooga, US, ⁸Revolution Medicines, Redwood City, US, ⁹Sanofi, Cambridge, US, ¹⁰GenHarp Clinical Solutions, LLC, Evergreen Park, US

12:00 - 12:00

77TiP - TRUST-II: A global phase II study for taletrectinib in ROS1 fusion positive lung cancer and other solid tumors

M. Nagasaka¹, S. Sugawara², C.-M. Choi³, T. Okamoto⁴, N. Yanagitani⁵, K. Nosaki⁶, T. Takahashi⁷, Y. Fujiwara⁸, H. Hayashi⁹, J. Khoury¹⁰, J. Nieva¹¹, A. Gabayan¹², L. Raez¹³, H. Chen¹⁴, A. Dimou¹⁵, N. Pennell¹⁶, G. Liu¹⁷, S.-H.I. Ou¹, T. Seto⁴, Y. Ohe¹⁸, ¹University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center, Orange, US, ²Sendai Kosei Hospital, Miyagi, JP, ³Asan Medical Center, Seoul, KR, ⁴NHO Kyushu Cancer Center, Fukuoka, JP, ⁵The Cancer Institute Hospital of JFCR, Tokyo, JP, ⁶National Cancer Center Hospital East, Chiba, JP, ⁷Shizuoka Cancer Center, Shizuoka, JP, ⁸Aichi Cancer Center Hospital, Nagoya, JP, ⁹Kindai University Hospital, Osaka-sayama, JP, ¹⁰American Institute of Research, Whittier, US, ¹¹University of Southern California Keck School of Medicine, Los Angeles, US, ¹²Beverly Hills Cancer Center, Los Angeles, US, ¹³Memorial Cancer Institute/ Florida Atlantic University (FAU), Miami, US, ¹⁴Roswell Park Comprehensive Cancer Center, Buffalo, US, ¹⁵Mayo Clinic, Rochester, US, ¹⁶Cleveland Clinic, Cleveland, US, ¹⁷Princess Margaret Cancer Centre, Toronto, CA, ¹⁸National Cancer Center Hospital, Tokyo, JP

12:00 - 12:00

78TiP - Clinical evaluation of NVL-520, a highly selective ROS1 inhibitor in patients with advanced ROS1-positive solid tumors: The phase 1/2 ARROS-1 study

B. Besse¹, M. Johnson², S.-H.I. Ou³, S. Gadgeel⁴, A. Spira⁵, J. Lin⁶, E. Felip⁷, A. Van Der Wekken⁸, A. Calles⁹, M.J. De Miguel¹⁰, D.R. Camidge¹¹, Y. Elamin¹², G. Lopes¹³, S. Liu¹⁴, J. Bauman¹⁵, D. Haggstrom¹⁶, G. Riley¹⁷, H. Pelish¹⁷, V. Zhu¹⁷, A. Drilon¹⁸, ¹Institut Gustave Roussy, Villejuif, FR, ²Sarah Cannon Research Institute, Nashville, US, ³University Of California Irvine Medical Center, Orange, US, ⁴Henry Ford Cancer Institute - Henry Ford Hospital, Detroit, US, ⁵Virginia Cancer Specialists Research Institute, US Oncology Research, Fairfax, US, ⁶Massachusetts General Hospital, Boston, US, ⁷Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, ES, ⁸University of Groningen, University Medical Centre Groningen, Groningen, NL, ⁹Hospital Universitario Gregorio Marañón, Madrid, ES, ¹⁰START Madrid-HM CIOCC, Madrid, ES, ¹¹University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, US, ¹²MD Anderson Cancer Center, Houston, US, ¹³Sylvester Comprehensive Cancer Center at the University of Miami and the Miller School of Medicine, Miami, US, ¹⁴Georgetown University, Washington, US, ¹⁵Fox Chase Cancer Center, Philadelphia, US, ¹⁶Levine Cancer Institute, Atrium Health, Charlotte, US, ¹⁷Nuvalent, Inc., Cambridge, US, ¹⁸Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

12:00 - 12:00

79TiP - A Phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations

F. Opdam¹, J. Heymach², M. Barve³, N. Gibson⁴, B. Sadrolhefazi⁵, J. Serra⁶, N.

Yamamoto⁷, ¹Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, NL, ²Department of Thoracic-Head and Neck Medical Oncology, Division of Cancer Medicine, MD Anderson Cancer Center, University of Texas, Houston, US, ³Mary Crowley Cancer Research, Dallas, US, ⁴Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, DE, ⁵Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, US, ⁶Boehringer Ingelheim España S.A., Barcelona, ES, ⁷National Cancer Center Hospital, Tokyo, JP

12:00 - 12:00 **83P - Pathologic complete response (pCR) after neoadjuvant (neoadj) chemoimmunotherapy (chemo+IO) in resectable non-small cell lung cancer (NSCLC): A systematic review and pooled analysis**

S. Rosner¹, C. Liu², P. Forde², C. Hu², ¹Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US, ²Johns Hopkins University, Baltimore, US

12:00 - 12:00 **84P - SHR-1316 vs placebo in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: A randomized, double-blind, multicenter, phase 1b/3 trial**

Y.-L. Wu¹, K. Chen², W. Xing³, Q. Chen⁴, L. Liu⁵, Q. Zhang⁶, D. Ge⁷, Y.-H. Liu⁸, X. Lin⁹, L. Wang⁹, Y. Huang⁹, W.-Z. Zhong⁸, ¹Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, ²Beijing Cancer Hospital, Beijing, CN, ³The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, CN, ⁴Zhejiang Cancer Hospital, Hangzhou, CN, ⁵West China Hospital of Sichuan University, Chengdu, CN, ⁶Jiangsu Cancer Hospital, Nanjing, CN, ⁷Zhongshan Hospital Fudan University, Shanghai, CN, ⁸Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, ⁹Jiangsu Hengrui Pharmaceuticals Co., Ltd, Shanghai, CN

12:00 - 12:00 **85P - Adjuvant osimertinib in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis**

W. Jie¹, Y.-L. Wu², S. Lu³, Q. Wang⁴, S. Li⁵, W. Zhong⁶, Q. Wang⁷, W. Li⁸, B. Wang⁹, J. Chen¹⁰, Y. Cheng¹¹, H. Duan¹², G. Li¹³, L. Shan¹⁴, Y. Liu¹⁵, X. Huang¹⁶, A. Atasoy¹⁶, J. He¹⁷, ¹Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN, ²Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN, ³Lung Cancer Center, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN, ⁴Zhongshan Hospital, Fudan University, Shanghai, CN, ⁵Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ⁶Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou, CN, ⁷Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, CN, ⁸The First Hospital of Jilin University, Changchun, Jilin, CN, ⁹Yangzhou University, Yangzhou, Jiangsu, CN, ¹⁰Tianjin Medical University General Hospital, Tianjin, CN, ¹¹Jilin Cancer Hospital, Changchun, CN, ¹²Zhongshan Hospital, Xiamen University, Xiamen, CN, ¹³GCP, Yunnan Cancer Hospital, Kunming, CN, ¹⁴Xinjiang Medical University Affiliated Cancer Hospital, Urumqi, CN, ¹⁵AstraZeneca, Shanghai, CN, ¹⁶AstraZeneca, Cambridge, GB, ¹⁷National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

12:00 - 12:00 **86P - Aumolertinib as adjuvant therapy in postoperative EGFR-Mutated non-**

small cell lung cancer

Q. Zhang, C. He, T. He, Y. Wang, W. Lv, J. Hu, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, CN

- 12:00 - 12:00 **87P - Patient reported physical function (PF) predicts long-term survival in early-stage NSCLC surgical patients**
C. Pompili¹, S. Omar¹, H. Hylias¹, A. Campisi², G. Velikova¹, L. Valuckiene³, A. Brunelli³,
¹University of Leeds, Leeds, GB, ²University Hospital Trust Verona, Verona, IT, ³St. James's University Hospital, Leeds, GB
- 12:00 - 12:00 **88P - Uncertain resection for localized cN0M0 non-small cell lung cancer: The crucial prognosis of suboptimal lymph node assessment**
R. Vergé, A. Rouch, C. Renaud, L. Mazzoni, M. Cazaux, P. Rabinel, L. Bouchet, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR
- 12:00 - 12:00 **89P - Treatment patterns, overall survival (OS), and disease-free survival (DFS) in early stage non-small cell lung cancer (NSCLC) following complete resection**
H. West¹, X. Hu², T. Burke², M. Walker³, Y. Wang³, A. Samkari², ¹City of Hope Comprehensive Cancer Center, Duarte, US, ²Merck & Co., Inc., Kenilworth, US, ³ConcertAI, Memphis, US
- 12:00 - 12:00 **90P - Disease-free survival (DFS) as a predictor of overall survival (OS) in completely resected early stage non-small cell lung cancer (NSCLC)**
H. West¹, X. Hu², T. Burke², M. Walker³, Y. Wang³, A. Samkari², ¹City of Hope Comprehensive Cancer Center, Duarte, US, ²Merck & Co., Inc., Kenilworth, US, ³ConcertAI, Memphis, US
- 12:00 - 12:00 **91P - Preexisting tumor host immunity delineates clinical outcomes in resectable non-small cell lung cancer**
P. Simoes Da Rocha¹, M. Rodrigo¹, L. Moliner², A. Ríos-Hoyo¹, L. Pinto¹, N. Navarro-Gorro¹, S. Menendez¹, A. Taus¹, A. Rodríguez¹, R. Aguiló¹, J. Belda¹, R. Del Rey-Vergara³, M. Galindo³, L. Comerma¹, E. Arriola¹, ¹Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ²The Christie NHS Foundation Trust, UK, GB, ³IMIM (Hospital del Mar Medical Research Institute), Barcelona, ES
- 12:00 - 12:00 **92P - Exploring immune dysfunction in surgically treated early stage NSCLC**
L. Sellmer¹, J. Kovács², J. Walter³, J. Kumbrink¹, J. Neumann¹, D. Kauffmann-Guerrero³, R. Kiefl¹, C. Schneider², A. Jung¹, J. Behr¹, A. Tufman³, ¹University Hospital LMU Munich, Munich, DE, ²University Hospital, LMU Munich, Munich, DE, ³LMU Klinikum der Universität München, Munich, DE
- 12:00 - 12:00 **93P - Noncancer-specific mortality in patients with stage IA1 NSCLC after surgical resection: The role of comorbidities in prognosis**
W. Huang, H.-Y. Deng, Y.-Q. Wang, Y.-F. Wang, K. Xu, M.-Y. Lin, J.-H. Weng, S.-K. He, Q. Zhou, West China Hospital, Sichuan University, Chengdu, CN
- 12:00 - 12:00 **94P - Preliminary outcome data for deep inspiratory breath hold guided**

stereotactic radiotherapy (SBRT) with robotic couch correction for early stage non-small cell lung cancers (NSCLC)

T. Basu, M. Senapati, J. Priyadharshni, R. Nair, U. Saxena, S. Rajurkar, HCG Cancer Center, Mumbai, IN

- 12:00 - 12:00 **95P - Role of postoperative follow-up with 18F-FDG PET/CT in asymptomatic NSCLC patients: A retrospective single institution study**
A. Kaumanns, D. König, A. Hojski, M. Cattaneo, A.-F. Chirindel, M. Tamm, D. Lardinois, S. Rothschild, University Hospital Basel, Basel, CH
- 12:00 - 12:00 **96P - Transbronchial microwave ablation: Important role in the battle of lung preservation for multifocal lung primaries or metastases**
J. Chan¹, R. Lau¹, A. Chang¹, C.M. Chu¹, T. Mok², C. Ng¹, ¹The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK, ²Prince of Wales Hospital - Li Ka Shing Specialist Clinics, Sha Tin, HK
- 12:00 - 12:00 **97P - TNFSF14 overexpression and poor prognosis in early stages of non-small cell lung cancer prognosis: Immune-checkpoint inhibitor databases-based study**
M.H.O. Safi¹, F. Ping², J. Liu³, ¹The first affiliated hospital of Dalian medical university, Dalian, CN, ²Dalian Medical University, Dalian city, CN, ³The first affiliated hospital of Dalian medical university, Dalian city, CN
- 12:00 - 12:00 **98P - Clinical characteristic of women under 55 years old who qualified for surgical treatment of lung cancer: Analysis of 1574 cases**
A. Trojnar¹, M. Zbytniewski², G. Gryszko², M. Cackowski², K. Woznica³, T. Orlowski², J. Domagala-Kulawik¹, D. Dziedzic², ¹Medical University of Warsaw, Warsaw, PL, ²National Research Institute of Chest Diseases, Warsaw, PL, ³Warsaw University of Technology, Warsaw, PL
- 12:00 - 12:00 **99P - The value of disease free survival (DFS) and osimertinib in adjuvant non-small cell lung cancer (NSCLC): An international Delphi consensus report**
M. Hardenberg, B. Patel, C. Matthews, Charles River Associates, Cambridge, GB
- 12:00 - 12:00 **100P - Physician perceptions of testing practices in patients with early and advanced stage EGFR mutation positive (EGFRm) NSCLC: A global survey**
J. Samol¹, T. Bailey², F. Moiseenko³, M. Paats⁴, I. Demedts⁵, M. Erman⁶, D. Kahangire⁷, V. Kozlov⁸, M. Mark⁹, J. Minatta¹⁰, S. Rajappa¹¹, M. Zukin¹², M. Madondo⁷, A. Taylor⁷, ¹Tan Tock Seng Hospital, Tan Tock Seng, SG, ²Adelphi, Macclesfield, GB, ³St Petersburg Academic University, St Petersburg, RU, ⁴Department of Pulmonary Medicine, Rotterdam, NL, ⁵AZ Delta Roeselare-Menen, Roeselare, BE, ⁶Hacettepe University Cancer Institute, Ankara, TR, ⁷AstraZeneca, Cambridge, GB, ⁸Novosibirsk Regional Clinical Oncology Center, Novosibirsk, RU, ⁹Kantonsspital Graubünden, Chur, CH, ¹⁰Hospital Italiano de Buenos Aires, Buenos Aires, AR, ¹¹Basavatarakam Indo American Cancer Hospital & Research Institute, Hyderabad, IN, ¹²Oncologia D'Or Rio de Janeiro, Rio de Janeiro, BR
- 12:00 - 12:00 **101P - Clinicopathological features and behavior of ground glass opacity lung cancer associated with cystic airspace**

Z. Yu¹, J. Li¹, C. Li¹, L. Liu¹, W. Liang¹, J. He², ¹State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, CN, ²The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, CN

- 12:00 - 12:00 **102P - Comparison of clinical characteristics and prognosis of incidentally detected and screening detected lung cancers**
S. Zo¹, S.H. Shin², B.-H. Jeong², K. Lee², H. Kim², O.J. Kwon², S.-W. Um², ¹Samsung Medical Center (SMC), Seoul, US, ²Samsung Medical Center (SMC), Seoul, KR
- 12:00 - 12:00 **103P - Effectiveness of artificial intelligence in retrospective COVID-19 lung CT analysis for lung cancer detection**
S. Pirgulov, Clinic "Scandinavia, Saint-Petersburg, RU
- 12:00 - 12:00 **104P - The potential for lung cancer detection in COVID-19 CT scans with AI technologies usage**
S. Zinovev, Nizhny Novgorod Regional Clinical Oncology Center, Nizhny Novgorod, RU
- 12:00 - 12:00 **105P - A model of workflow for radiomics signature of stage III non-small cell lung cancer (NSCLC) patients (pts)**
A. Ferro¹, G. Pasello², E. Scagliori¹, F. Caumo³, M. Costa⁴, S. Frega², M. Sepulcri², L. Bonanno², F. Rea⁵, V. Guarneri⁵, G. Gennaro³, ¹Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ²IOV - Istituto Oncologico Veneto IRCCS, Padova, IT, ³Veneto Institute of Oncology - IRCCS, Padova, IT, ⁴Tecnologie Avanzate TA Srl, Udine, IT, ⁵University of Padua, Padova, IT
- 12:00 - 12:00 **106P - Generation of synthetic ground glass opacities (GGOs) using generative adversarial networks (GANs)**
Z. Wang¹, Z. Zhang², L. Hendriks³, R. Miclea³, H. Gietema³, J. Schoenmaekers³, L. Wee¹, A. Dekker¹, A. Traverso¹, ¹Maastrro, Maastricht, NL, ²Maastrro Clinic, Maastricht, NL, ³Maastricht University Medical Center (MUMC), Maastricht, NL
- 12:00 - 12:00 **107P - Application of contrast clearance analysis (CCA) to assess viable tumour in non-small cell lung cancer (NSCLC) brain metastases post-stereotactic radiosurgery (SRS)**
S. Mohamedkhan¹, N. Williams¹, T. Millard¹, N. Rosenfelder¹, B. Sharma¹, A. Minchom², ¹The Royal Marsden Hospital (Sutton), Sutton, GB, ²London, GB
- 12:00 - 12:00 **110P - Updated efficacy and safety of entrectinib in patients (pts) with NTRK fusion-positive (NTRK-fp) NSCLC**
B.C. Cho¹, C.-H. Chiu², E. Massarelli³, S.P. Chawla⁴, G.L. Buchschacher Jr⁵, K. Goto⁶, S.-W. Kim⁷, T.R. Overbeck⁸, H.H.F. Loong⁹, C.E. Chee¹⁰, P. Garrido Lopez¹¹, S. Heinzmann¹², B. Pitcher¹³, T. John¹⁴, ¹Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KR, ²Taipei Veterans General Hospital, Taipei, TW, ³City of Hope Comprehensive Cancer Center, Duarte, US, ⁴Sarcoma Oncology Center, Santa Monica, US, ⁵Kaiser Permanente Southern California, Los Angeles Medical Center, Los Angeles, US, ⁶National Cancer Center Hospital East, Kashiwa, Chiba, JP, ⁷Asan Medical Center, University of Ulsan College of Medicine, Seoul, KR, ⁸University Medical Center

Göttingen, Göttingen, DE, ⁹The Chinese University of Hong Kong, Hong Kong, HK, ¹⁰National University Cancer Institute, Singapore, SG, ¹¹Hospital Universitario Ramon y Cajal, Madrid, ES, ¹²F. Hoffmann-La Roche Ltd, Basel, CH, ¹³F. Hoffmann-La Roche Ltd, Mississauga, CA, ¹⁴Peter McCallum Cancer Center, Melbourne, AU

- 12:00 - 12:00 **111P - Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours**
- S. Lu¹, C.-H. Chiu², Y. Yu³, H.H.F. Loong⁴, C.C. Lin⁵, X. Hu⁶, X. Dong⁷, J. Li⁸, J. Zhao⁹, S. Ye-Hui¹⁰, Z. Zhang¹¹, N. Zhao¹², J. Xia¹², D. Wang¹², Y. Fan¹³, ¹Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN, ²Taipei Veterans General Hospital, Taipei, TW, ³Harbin Medical University Cancer Hospital, Harbin, CN, ⁴The Chinese University of Hong Kong, Hong Kong, HK, ⁵National Taiwan University Hospital, Taipei, TW, ⁶Shanghai Cancer Center, Fudan University, Shanghai, CN, ⁷Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, CN, ⁸Department of Medical Oncology, Sichuan Cancer Hospital, Chengdu, CN, ⁹Peking University Cancer Hospital & Institute, Beijing, CN, ¹⁰Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin Medical University, Tianjin, CN, ¹¹F. Hoffmann-La Roche Limited, Beijing, CN, ¹²F. Hoffmann-La Roche Limited, Shanghai, CN, ¹³Zhejiang Cancer Hospital, Hangzhou, CN
- 12:00 - 12:00 **112P - Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation**
- I. Bondarenko¹, A. Sezer², S. Kilickap³, M. Gümüs⁴, M. Özgüroğlu⁵, M. Gogishvili⁶, X. He⁷, G. Gullo⁷, P. Rietschel⁷, R. Quek⁷, ¹Dnipropetrovsk Medical Academy, Dnipro, UA, ²Baskent University, Adana, TR, ³Hacettepe University Cancer Institute, Ankara, TR, ⁴Istanbul Medeniyet University, Istanbul, TR, ⁵Istanbul University-Cerrahpasa, Cerrahpasa School of Medicine, Istanbul, TR, ⁶High Technology Medical Centre, University Clinic Ltd, Tbilisi, GE, ⁷Regeneron Pharmaceuticals, Inc., Tarrytown, US
- 12:00 - 12:00 **113P - Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on durvalumab eligibility and safety profile**
- F. Cortiula¹, D. De Ruysscher², S. Dursun³, M. Steens⁴, G. Bootsma⁴, R. Canters¹, I. Rinaldi¹, V. Taasti¹, R. Houben¹, K. Reynnders¹, S. Peeters¹, A. Angrisani¹, D. Hattu¹, L. Hendriks⁵, ¹Maastricht University Medical Center+, Maastricht, NL, ²Maastro Clinic, Maastricht, NL, ³GROW-School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, NL, ⁴Zuyderland Medical Center, Heerlen, NL, ⁵Maastricht University Medical Center (MUMC), Maastricht, NL
- 12:00 - 12:00 **114P - Preliminary results of the “Blue Sky Radiomics” study on stage III NSCLC patients treated with chemo-radiation and consolidation immunotherapy**
- A.R. Filippi¹, A. Lancia¹, O. Oneta¹, N. Tsoutzidis², C. Bortolotto¹, E. Ali³, V. Bartolomeo⁴, S. La Mattina⁵, P. Borghetti⁶, G. Stella¹, F. Agustoni¹, R. Sun⁷, E. Deutsch⁷, A. Lascialfari⁴, S. Figini⁴, P. Pedrazzoli¹, L. Preda¹, S. Walsh⁸, ¹Fondazione IRCCS Policlinico San Matteo, Pavia, IT, ²Radiomics, Liege, BE, ³University of Perugia, Perugia, IT, ⁴University of Pavia, Pavia, IT, ⁵University of Brescia, Brescia, IT, ⁶Azienda

Ospedaliera Spedali Civili di Brescia, Brescia, IT, ⁷Institut Gustave Roussy, Villejuif, FR,
⁸Radiomics, Liège, BE

- 12:00 - 12:00 **115P - Concurrent versus sequential immune checkpoint inhibition in stage III NSCLC patients treated with chemoradiation**
L. Käsmann¹, J. Taugner¹, C. Eze¹, J. Guggenberger¹, B. Flörsch¹, S. Kenndoff¹, A. Tufman¹, N. Reinmuth², C. Belka³, F. Manapov¹, ¹LMU Klinikum der Universität München, Munich, DE, ²Asklepios-Fachklinikum, Gauting, DE, ³University of Munich LMU, Munich, DE
- 12:00 - 12:00 **116P - Real-world outcomes with durvalumab (durva) after chemoradiotherapy (CRT) in patients with unresectable Stage III NSCLC (SPOTLIGHT)**
M. Mooradian¹, A. Allen², L. Cai², Y. Xiao², P. Chander², ¹Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, US, ²AstraZeneca, Gaithersburg, US
- 12:00 - 12:00 **117P - Prognostic value of new grading system in resected lung adenocarcinoma after neoadjuvant therapy**
H. E., L. Hou, J. Wu, D. Zhao, C. Chen, Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN
- 12:00 - 12:00 **118P - Impact of grade 2 pneumonitis (G2+ PNS) on patient reported outcomes (PROs) with durvalumab (D) after chemoradiotherapy (CRT) in unresectable stage III NSCLC**
R. Hui¹, J. Naidoo², M. Garassino³, H. Broadhurst⁴, N. Patel⁵, M. Newton⁶, P. Thiagarajah⁵, J. Vansteenkiste⁷, ¹Westmead Hospital and the University of Sydney, Sydney, AU, ²Sidney Kimmel Comprehensive Cancer Center at John Hopkins University, Baltimore, MD, USA and Beaumont Hospital and RCSI University of Health Sciences, Dublin, IE, ³University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US, ⁴Plus-Project, Knutsford, GB, ⁵AstraZeneca, Cambridge, GB, ⁶AstraZeneca, Gaithersburg, US, ⁷University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
- 12:00 - 12:00 **119P - Evolution of the management of stage III non-small cell lung cancer (NSCLC): A single center real-world scenario over 10 years**
A. Ferro¹, M. Sepulcri², M. Schiavon³, E. Scagliori¹, G. Gennaro⁴, M. Costa⁵, L. Bonanno¹, S. Frega¹, A. Dal Maso³, F. Calabrese³, F. Rea³, F. Caumo⁴, V. Guarneri³, G. Pasello⁶, ¹Veneto Institute of Oncology IOV - IRCCS, Padova, IT, ²Veneto Institute of Oncology IOV-IRCCS, Padova, IT, ³University of Padua, Padova, IT, ⁴Veneto Institute of Oncology - IRCCS, Padova, IT, ⁵Tecnologie Avanzate TA Srl, Udine, IT, ⁶IOV - Istituto Oncologico Veneto IRCCS, Padova, IT
- 12:00 - 12:00 **120P - Efficacy of postoperative radiotherapy (PORT) in stage 3A-N2 non-small cell lung cancer: Meta-analysis of randomized controlled studies**
Y. Ergün¹, G. Uçar², Y. Açıkgöz², M. Dirikoç², S. Aktürk Esen², M. Bardakçi², C. Karaçin³, D. Uncu², ¹Batman Training and Research Hospital, Batman, TR, ²Ankara City Hospital, Ankara, TR, ³Dr. AY Ankara Oncology Training and Research Hospital, Ankara, TR

- 12:00 - 12:00 **121P - Treatment of unresectable stage III NSCLC: Real-world study and literature review**
S. Verfaillie, A.-S. Van De Velde, P. Berkovic, C. Doooms, K. Nackaerts, J. Vansteenkiste, M. Lambrecht, E. Wauters, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE
- 12:00 - 12:00 **122TiP - Phase III study of durvalumab with SBRT for unresected stage I/II, lymph-node negative NSCLC (PACIFIC-4/RTOG 3515)**
C. Robinson¹, L. Xing², H. Tanaka³, S. Tasaka⁴, S. Badiyan¹, H. Nasrallah⁵, T. Biswas⁶, M. Shtivelband⁷, W. Schuette⁸, A. Shi⁹, A. Hepner¹⁰, K. Barrett¹¹, J. Rigas¹⁰, H. Jiang¹⁰, S. Lin¹², ¹Washington University in St. Louis/Siteman Cancer Center, St. Louis, US, ²Shandong Cancer Hospital, Shandong First Medical University, Jinan, CN, ³Niigata Cancer Center Hospital, Niigata, JP, ⁴Hirosaki University School of Medicine and Hospital, Hirosaki, JP, ⁵Rambam Health Care Campus, Haifa, IL, ⁶University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, US, ⁷Ironwood Cancer and Research Centers, Chandler, US, ⁸Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH, Halle, DE, ⁹Beijing Cancer Hospital, Beijing, CN, ¹⁰AstraZeneca, Gaithersburg, US, ¹¹AstraZeneca, Cambridge, GB, ¹²The University of Texas MD Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **123P - Clinical and environment factors impacting malignant pleural mesothelioma prognosis**
N. Deboever¹, D. Mcgrail¹, N. Zhou¹, M. Altan¹, J. Olivia¹, E. Parra¹, J. Zhang¹, P. Lee¹, R. Rajaram¹, W. Hofstetter¹, A. Vaporciyan¹, R. Mehran¹, D. Rice¹, K. Tomczak¹, A. Weissferdt¹, A. Tsao¹, C. Haymaker¹, B. Sepesi², ¹MD Anderson Cancer Center, Houston, US, ²The University of Texas M. D. Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **124P - Comparison of survival among multimodality treatment regimens in malignant pleural mesothelioma patients in an integrated health system**
K. Banks¹, S. Ossowski², Y.-Y. Hung³, D. Hsu¹, S. Ashiku⁴, A. Patel⁴, J. Velotta⁴, J.M. Suga⁵, ¹University of California San Francisco- East Bay, Oakland, US, ²Kaiser San Francisco Medical Center, San Francisco, US, ³Kaiser Permanente Northern California, Oakland, US, ⁴Kaiser Permanente Oakland Medical Center, Oakland, US, ⁵Kaiser Permanente Vallejo Medical Center, Vallejo, US
- 12:00 - 12:00 **125P - Radiomic signature from baseline CT scan to predict initial response to treatment in advanced/unresectable pleural mesothelioma: Preliminary data**
A. Catino¹, A. Fanizzi², P.P.S. Perrotti², P. Pizzutilo², M. Montrone², D. Galetta², R. Massafra², ¹Istituto Tumori Giovanni Paolo II, Bari, IT, ²Istituto Tumori Giovanni Paolo II, BARI, IT
- 12:00 - 12:00 **126P - Characteristics and postoperative trajectory of patients requiring ICU admission following radical surgery for mesothelioma**
K. Chandarana, M. Koulouroudias, N. Chantima, E. Caruana, A. Nakas, Glenfield Hospital - University Hospitals of Leicester NHS Trust, Leicester, GB
- 12:00 - 12:00 **127P - Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer**

(NSCLC)?

L. Hendriks¹, S. Keek², A. Chatterjee², J. Belderbos³, G. Bootsma⁴, B. Van Den Borne⁵, A.-M. Dingemans⁶, H. Gietema¹, H. Groen⁷, G. Herder⁸, C. Pitz⁹, J. Praag¹⁰, D. De Ruyscher¹¹, J. Schoenmaekers¹, H. Smit¹², J. Stigt¹³, M. Westenend¹⁴, H. Zeng¹¹, H. Woodruff², P. Lambin², ¹Maastricht University Medical Center (MUMC), Maastricht, NL, ²Maastricht University, Maastricht, NL, ³NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL, ⁴Zuyderland Medical Center, Heerlen, NL, ⁵Catharina Hospital Eindhoven, Eindhoven, NL, ⁶Erasmus MC - University Medical Center, Rotterdam, NL, ⁷UMCG - University Medical Center Groningen, Groningen, NL, ⁸Meander Medisch Centrum, Amersfoort, NL, ⁹Laurentius Hospital, Roermond, NL, ¹⁰Erasmus MC, Rotterdam, NL, ¹¹Maastro Clinic, Maastricht, NL, ¹²Rijnstate Hospital, Arnhem, NL, ¹³Isala Hospital, Zwolle, NL, ¹⁴VieCuri, Venlo, NL

12:00 - 12:00 **128P - Surgical management of lung metastases: A work-in-progress report from an international ESTS research group**

E. Prisciandaro¹, L. Bertolaccini², D. Van Raemdonck¹, J. Moons¹, P. De Leyn¹, H. Decaluwé¹, L. Spaggiari², L. Ceulemans¹, ¹University Hospitals Leuven, Leuven, BE, ²European Institute of Oncology, Milan, IT

12:00 - 12:00 **129P - Regulatory dendritic cells correlate with an altered T cell distribution and regulatory T cell phenotype in metastatic lymph nodes of NSCLC patients**

A. Raniszewska¹, I. Kwiecien¹, E. Rutkowska¹, R. Sokolowski¹, J. Bednarek¹, P. Rzepecki¹, J. Domagala-Kulawik², ¹Military Institute of Medicine, Warsaw, PL, ²Medical University of Warsaw, Warsaw, PL

12:00 - 12:00 **130P - Metastasis-on-chip: 3D human microvasculature network to study extravasation dynamics of lung cancer in vitro**

S. Zeinali¹, K. Rechberger¹, C. Dubey², R. Gashi¹, T. Marti², P. Dorn², O. Guenat¹, ¹University of Bern, Bern, CH, ²University Hospital of Bern, Bern, CH

12:00 - 12:00 **132P - 20 years of real life nationwide epidemiological data on lung cancer in non-academic French public hospitals: KBP-2020-CPHG compared to 2000 and 2010 studies**

D. Debieuvre¹, J.B. Auliac², O. Bylicki³, L. Moreau⁴, R. Corre⁵, J. Pinsolle⁶, A. Bizieux Thamiy⁷, S. Schneider⁸, B. Godbert⁹, P.A. Renault¹⁰, P. Brun¹¹, M. Bernardi¹², E. Briens¹³, M. Lepoulain Doublier¹⁴, B. Delclaux¹⁵, L. Petit¹⁶, J.L. Bizec¹⁷, G. Milliet De Faverges¹⁸, F. Al Freijat¹⁹, J. Quieffin²⁰, ¹GHRMSA, Mulhouse, FR, ²CHI - Centre Hospitalier Intercommunal de Créteil, Créteil, Cedex, FR, ³Hôpital D'instruction Des Armées Ste Anne, TOULON, FR, ⁴Hopitaux Civils de Colmar, Colmar, FR, ⁵CH de Cornouaille - Hopital Laennec, Quimper, FR, ⁶Centre Hospitalier Chambéry, Chambéry, FR, ⁷Centre Hospitalier La Roche-sur-Yon, La Roche-sur-Yon, FR, ⁸Centre Hospitalier de la Côte Basque, Bayonne, FR, ⁹Hopital Robert Schuman, Vantoux, FR, ¹⁰CH Francois Mitterrand, Pau, FR, ¹¹Centre Hospitalier Valence, Valence, FR, ¹²Centre Hospitalier Aix-en-Provence, Aix-en-Provence, FR, ¹³Hospital Center De Saint Brieuc, Saint-Brieuc, FR, ¹⁴Centre Hospitalier Corvisart, Charleville Mézières, FR, ¹⁵Centre Hospitalier Troyes - Hopital des Hauts Clos, Troyes, FR, ¹⁶Centre Hospitalier Alpes Leman, Contamine-sur-Arve, FR, ¹⁷Centre Hospitalier Bretagne Atlantique - Centre d'Oncologie Saint-Yves, Vannes, Cedex, FR, ¹⁸Centrer Hospitalier Pierre Beregovoy, Nevers, FR, ¹⁹Hopital Nord

Franche Comte, Belfort, FR, ²⁰Centre Hospitalier Jacques Monod, Le Havre, FR

- 12:00 - 12:00 **133P - Trends in incidence and mortality of lung cancer in Switzerland: Possible explanations and open questions**
D. Frisone¹, J. Sandoval¹, T. Olivier², A. Friedlaender³, A. Addeo¹, ¹HUG - Hopitaux Universitaires de Geneve, Geneva, CH, ²University of California, San Francisco, US, ³Clinique Générale Beaulieu, Geneva, CH
- 12:00 - 12:00 **134P - Effectiveness of non-pharmacologic strategies for parental smoking cessation to protect children: A systematic review and meta-analysis**
J. Caduhada, USTH - University of Santo Tomas Hospital, valenzuela, PH
- 12:00 - 12:00 **135P - Patterns of care and outcomes in immigrants with non-small cell lung cancer**
L. Willen¹, A. Berglund², S. Bergström³, J. Isaksson⁴, M. Bergqvist⁵, G. Wagenius⁶, M. Lambe⁷, ¹Umeå University, Umeå, SE, ²EpiStat AB, Uppsala, SE, ³Sjukhus Gavle, Gavle, SE, ⁴Uppsala University, Uppsala, SE, ⁵Umea University, Umea, SE, ⁶Karolinska University Hospital, Solna, SE, ⁷Karolinska Institute, Stockholm, SE
- 12:00 - 12:00 **136P - Lung cancer epidemiology and survival outcomes in Vojvodina, Serbia**
D. Bokan, B. Zaric, T. Kovacevic, J. Djekic Malbasa, I. Andrijevic, Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, RS
- 12:00 - 12:00 **137P - Epidemiology and histological classification of lung cancer patients in Zimbabwe: A five-year retrospective study at Parirenyatwa Radiotherapy Centre, Harare**
T. Mazhindu¹, N. Ndlovu¹, A. Nyamhunga¹, S. Chibonda², M. Pepukai³, A.M. Nyakabau¹, W. Kadzatsa⁴, ¹University of Zimbabwe, Faculty of Medicine and Health Sciences, Harare, ZW, ²Parirenyatwa Group of Hospitals, harare, ZW, ³Ministry of Health and Child care, Harare, ZW, ⁴University of Zimbabwe, Faculty of Medicine and Health Sciences, harare, ZW
- 12:00 - 12:00 **138P - Prevalence and characteristics of lung cancer in families harboring pathogenic germline variants in cancer predisposing genes**
J.C. Laguna Montes, B. Pastor, L. Moreno, V.M. Albarran Artahona, M. Potrony, A. Sánchez, E. Grau, L. Gonzalez-Aguado, J. Oriola, R. Reyes, D. Martínez, N. Vinolas Segarra, L. Gaba, B. Adamo, N. Reguart Aransay, J.A. Puig-Butillé, C. Teixido, L. Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, ES
- 12:00 - 12:00 **139P - KRAS-G12C NSCLC linked to female sex and high risk of CNS metastasis: Real-world data from the National Swedish Lung Cancer Registry 2016-2019**
J. Isaksson¹, A. Berglund², K. Louie³, A. Hamidian⁴, A. Edsjö⁵, M. Johansson⁶, A. Hallqvist⁷, G. Wagenius⁸, L. Willen⁶, J. Botling⁹, ¹Uppsala University, Uppsala, SE, ²EpiStat AB, Uppsala, SE, ³Amgen Ltd, Uxbridge, GB, ⁴Amgen AB, Solna, SE, ⁵Region Skåne, Lund, SE, ⁶Umeå University, Umeå, SE, ⁷Institute of Clinical Sciences-Sahlgrenska University Hospital, Göteborg, SE, ⁸Karolinska University Hospital, Solna, SE, ⁹University Hospital Uppsala/Akademiska Sjukhuset, Uppsala, SE

- 12:00 - 12:00 **140P - Development and validation of nomograms based on clinical characteristics and CT reports for preoperative prediction of precision lymph node dissection in lung cancer**
H. Tang, L. Xiong, X. Zhou, J. Zhao, Zhongnan Hospital of Wuhan University, Wuhan, CN
- 12:00 - 12:00 **142P - Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CANTABRICO): Treatment patterns of chemotherapy combination phase with durvalumab**
D. Isla¹, E. Arriola², M.R. Garcia Campelo³, C. Martí⁴, P. Diz Tain⁵, A.L. Moreno Vega⁶, M. Piqueras⁷, L. León⁸, V. Gutierrez Calderon⁹, J. Oramas Rodriguez¹⁰, M. Majem¹¹, A. Sanchez-Hernandez¹², C. Aguado De La Rosa¹³, R. Alvarez Cabellos¹⁴, J.L. Marti-Ciriquian¹⁵, A. Moreno Paul¹⁶, M. Gonzalez Cordero¹⁷, Á. Callejo Mellén¹⁸, L. Baez¹⁸, J. Zugazagoitia¹⁹, ¹Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES, ²Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ³Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES, ⁴Hospital universitari de sant joan de reus, reus, ES, ⁵Complejo Asistencial Universitario de León, Leon, ES, ⁶Hospital Universitario Reina Sofía, Cordoba, ES, ⁷Hospital Universitario Marques de Valdecilla, Santander, ES, ⁸Complejo hospitalario universitario de Santiago, Santiago de Compostela, ES, ⁹Hospital Regional Universitario Málaga Carlos Haya, Malaga, ES, ¹⁰Hospital Universitario de Canarias, San Cristobal de la Laguna, ES, ¹¹Hospital de la Santa Creu i Sant Pau, Barcelona, ES, ¹²Consorcio Hospitalario Provincial de Castellón, Castellon de la Plana, ES, ¹³Hospital Clinico Universitario San Carlos, Madrid, ES, ¹⁴Hospital Virgen de la Salud, Toledo, ES, ¹⁵Hospital General Universitario de Alicante, Alicante, ES, ¹⁶Hospital Galdako-Usansolo, Galdako, ES, ¹⁷Hospital Universitario de Badajoz, Badajoz, ES, ¹⁸AstraZeneca Farmacéutica Spain S.A., Madrid, ES, ¹⁹Hospital Universitario 12 de Octubre, Madrid, ES
- 12:00 - 12:00 **143P - Efficacy and safety of the Anti-PD-L1 monoclonal antibody socazolimab in combination with carboplatin and etoposide for extensive-stage small cell lung cancer: Results from the phase Ib clinical trial**
S. Lu¹, Z. Chen², Z. Li², Z. Zhou², Y. Yu², X. Ai², Y. Zhao², X. Niu², J. Cui³, R. Guo⁴, B. Li⁵, X. Dai⁵, Y. Li⁵, M. Wong⁵, R. Ng⁵, Z. Zhao⁵, ¹Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN, ²Shanghai Chest Hospital, Shanghai, CN, ³The First Hospital of Jilin University, Changchun, CN, ⁴Jiangsu Province Hospital, Nanjing, CN, ⁵Lee's Pharmaceutical Holdings Limited, Hong Kong, HK
- 12:00 - 12:00 **144P - Real-world data of consolidative radiotherapy for extensive stage (ES)-SCLC treated by chemo-immunotherapy (chemo-IO)**
S. Daher¹, A. Allen², Y. Rottenberg³, H. Nasrallah⁴, L. Yosef², P. Blumenfeld³, M. Wollner⁴, S. Appel⁵, H. Nechushtan³, M. Moskovitz⁶, J. Bar¹, A. Zer⁴, ¹Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, IL, ²Rabin Medical Center, Petah Tikva, IL, ³Hadassah University Hospital, Jerusalem, IL, ⁴Rambam Health Care Campus, Haifa, IL, ⁵Chaim Sheba Medical Center, Ramat Gan, IL, ⁶Rambam Health Care Campus, Hifa, IL
- 12:00 - 12:00 **145P - Clinical outcomes of atezolizumab in combination with etoposide/platinum for extensive-stage small cell lung cancer in China: A real-world, multi-center, retrospective, controlled study**

M. Zhuo¹, H. Chen¹, X. Ma¹, J. Liu², Y. Yang³, Y. Fang⁴, L. Wang⁵, J. Zhao¹, ¹Peking University Cancer Hospital & Institute, Beijing, CN, ²Shandong Cancer Hospital and Institute Affiliated to Shandong University, Jinan, CN, ³The 2nd Affiliated Hospital of Harbin Medical University, Harbin, CN, ⁴Sir Run Run Shaw Hospital Zhejiang University School of Medicine, Hangzhou, CN, ⁵Baotou Cancer Hospital, Baotou, CN

12:00 - 12:00 **146P - Impact of heart, lung and oesophageal doses on overall survival (OS) of small cell lung cancer (SCLC) patients following radical chemo-radiotherapy (RT)**

B. Tahir¹, J. Reilly², J. Tay³, H. Clinch³, N. Boindala³, J. Hughes³, S. Riley³, P. Roxby³, S. Tozer-Loft³, T. Aung³, M. Qureshi³, T. Das³, M. Hatton³, ¹The University of Sheffield, Sheffield, GB, ²The University of Sheffield, Sheffield, GB, ³Weston Park Cancer Centre, Sheffield, GB

12:00 - 12:00 **147P - Chemo-immunotherapy with or without consolidative radiotherapy in extensive stage small cell lung cancer: An initial report of clinical outcome and safety**

A. Bruni¹, F. Bertolini², E. D'Angelo¹, F. Barbieri², J. Imbrescia¹, L. Trudu³, A. Cappelli⁴, F. Lohr⁴, M. Dominici³, G. Guaitoli⁵, ¹University Hospital "Policlinico" of Modena, Modena, IT, ²University Hospital of Modena, Modena, IT, ³University of Modena and Reggio Emilia - University Hospital "Policlinico" of Modena, Modena, IT, ⁴University of Modena and Reggio Emilia - University Hospital "Policlinico" of Modena, Modena, IT, ⁵Ph. D. Program Clinical and Experimental Medicine (CEM), Department of biomedical Metabolic and Neural Sciences, University of Modena and Reggio Emilia - "Policlinico" Hospital of Modena, Modena, IT

12:00 - 12:00 **148P - Pathological stage N1 limited-stage small-cell lung cancer patients can benefit from surgical resection**

L. Yu, J. Xu, R. Qiao, B. Han, H. Zhong, R. Zhong, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN

12:00 - 12:00 **149P - Total metabolic tumor volume: A new potential prognostic factor in SCLC**

E. Andrini¹, G. Lamberti², G. Argalia³, E. Fortunati³, V. Ambrosini³, S. Fanti³, A. Ardizzoni⁴, D. Campana⁴, ¹Department of Experimental Diagnostic and Specialized Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, IT, ²Division of Medical Oncology, IRCCS Azienda Ospedaliero—Universitaria di Bologna, 40138 Bologna, Italy, Bologna, IT, ³IRCCS Policlinico Sant'Orsola Malpighi, Bologna, IT, ⁴Division of Medical Oncology, IRCCS Azienda Ospedaliero—Universitaria di Bologna, Bologna, IT

12:00 - 12:00 **150P - Monitoring of PD-L1 expression on circulating immune cells of patients with small cell lung cancer (SCLC) receiving first-line treatment: Prognostic implications**

M. Papadaki¹, M.-N. Nikolarakou¹, E. Vorrias², E.-E. Kapetanaki¹, D. Kalapanida², D. Mavroudis², S. Agelaki², ¹UOC - University of Crete, Heraklion, GR, ²University General Hospital of Heraklion, Heraklion, GR

12:00 - 12:00 **151P - Real world patient eligibility for lurbinectedin / doxorubicin in small cell lung cancer**

R. Rittberg¹, B. Leung¹, Z. Al-Hashami², C. Ho¹, ¹BC Cancer, Vancouver, CA, ²Sultan Qaboos University, Muscat, OM

12:00 - 12:00 **152P - Immunotherapy for extensive-stage SCLC: Uncovering clinical gaps in physician knowledge and practice**

V. Harvey-Jones¹, A. Furedy¹, J. Vandenbroucq¹, M. Reck², ¹Medscape, Global Education, London, GB, ²Krankenhaus Grosshansdorf, Grosshansdorf, DE

12:00 - 12:00 **153P - Safety profile and associated costs of therapies for relapsed small cell lung cancer in Switzerland**

M. Joerger¹, B. Garcia San Andres², N.-N. Mederos-Alfonso³, Y. Metaxas⁴, E. Brock⁵, ¹Kantonsspital St. Gallen, St. Gallen, CH, ²Pharma Mar, S.A., Madrid, ES, ³CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH, ⁴KSGR - Kantonsspital Graubünden, Chur, CH, ⁵Healthecon AG, Basel, CH

12:00 - 12:00 **154TiP - AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)**

Y. Lu¹, Y. Gong¹, J.-H. Kang², J. Whan Ree³, X. Chen³, X. Lin³, J. Zhang³, H. Borghaei⁴, ¹West China School of Medicine, Sichuan University, Chengdu, China; Department of Thoracic Oncology and Laboratory of Clinical Cell Therapy and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, CN, ²Department of Medical Oncology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, KR, ³BeiGene (Beijing) Co., Ltd., Beijing, CN, ⁴Fox Chase Cancer Center, Philadelphia, US

12:00 - 12:00 **155TiP - Phase II study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE[®]) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)**

S. Ramalingam¹, H. Akamatsu², F. Blackhall³, H. Borghaei⁴, H.-D. Hummel⁵, M. Johnson⁶, M. Reck⁷, Y. Zhang⁸, D. Jandial⁸, S. Cheng⁸, L. Paz-Ares⁹, ¹Winship Cancer Institute of Emory University, Atlanta, US, ²Wakayama Medical University Hospital, Wakayama, JP, ³The Christie NHS Foundation Trust, Manchester, GB, ⁴Fox Chase Cancer Center, Philadelphia, US, ⁵Universitätsklinikum Würzburg, Comprehensive Cancer Center Mainfranken, Würzburg, DE, ⁶Sarah Cannon Research Institute, Nashville, US, ⁷Krankenhaus Grosshansdorf, Grosshansdorf, DE, ⁸Amgen Inc., Thousand Oaks, US, ⁹Hospital Universitario 12 de Octubre, Madrid, ES

12:00 - 12:00 **156TiP - An open-label, single-arm, phase II study evaluating the efficacy and safety of niraparib combined with radiotherapy and teriprizumab in patients with recurrent small cell lung cancer**

W. Zeng, C. Xie, Zhongnan Hospital of Wuhan University, Wuhan, CN

12:00 - 12:00 **158P - Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry**

G. Mountzios¹, D. Planchard², G. Metro³, A. Prelaj⁴, D. Tsiouda⁵, W. Shalata⁶, M.

Riudavets², P. Christopoulos⁷, N. Girard⁸, V.M. Albarran Artahona⁹, M.R. Garcia Campelo¹⁰, K. Samitas¹¹, G.L. Banna¹², I. Boukovinas¹³, A. Agbarya¹⁴, A. Koumarianou¹⁵, E.I. Perdikouri¹⁶, P. Kosmidis¹⁷, M. Reck¹⁸, G. Lo Russo¹⁹, ¹Henry Dunant Hospital Centre, Athens, GR, ²Institut Gustave Roussy, Villejuif, FR, ³Ospedale Santa Maria della Misericordia, Perugia, Italy, Bologna, IT, ⁴Thoracic Oncology Unit, Medical Oncology Department 1, Fondazione IRCCS Istituto Nazionale Tumori, Milan, IT, ⁵Theageneion Hospital, Thessaloniki, GR, ⁶The Legacy Heritage Center & Dr. Larry Norton Institute, Soroka Medical Center and Ben-Gurion University of the Negev, Beer Sheva, Israel., Beer Sheva, IL, ⁷Thoraxklinik Heidelberg gGmbH, Heidelberg, DE, ⁸Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR, ⁹Hospital Clinic y Provincial de Barcelona, Barcelona, ES, ¹⁰University Hospital A Coruña, CHUAC, A Coruña, ES, ¹¹7th Oncology Department, Sotiria Thoracic Hospital, Athens, GR, ¹²IRCCS - Istituto di Candiolo - FPO, Candiolo, IT, ¹³Bioclinic Oncology Unit of Thessaloniki, Thessaloniki, GR, ¹⁴Institute of Oncology, Bnai Zion Medical Center, Haifa, Israel, Haifa, IL, ¹⁵Department of Medical Oncology, Attikon University Hospital, Athens, GR, ¹⁶General Hospital of Volos "Achilopouleio", Volos, GR, ¹⁷Hygeia Hospital, Marousi, GR, ¹⁸Krankenhaus Grosshansdorf, Grosshansdorf, DE, ¹⁹Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT

- 12:00 - 12:00 **159P - ReWARD study - Real world ALK resistance data: A single center experience**
U. Batra, S. Nathany, M. Sharma, H. Singh, A. Mehta, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN
- 12:00 - 12:00 **160P - LungMetrics India: Molecular epidemiology and testing patterns in 4,773 non squamous NSCLC patients**
U. Batra, S. Nathany, J. Jose, M. Sharma, A. Mehta, A. Bansal, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN
- 12:00 - 12:00 **161P - Bayesian network structure for predicting two-year survival inpatients diagnosed with non small cell lung cancer**
B. Osong, A. Dekker, L. Wee, J. Van Soest, I. Bermejo, Maastricht, Maastricht, NL
- 12:00 - 12:00 **162P - A CT radiomics model to predict overall survival following curative-intent radiotherapy for stage I-III non-small cell lung cancer**
S. Hindocha¹, T. Charlton², K. Linton-Reid³, B. Hunter¹, C. Chan¹, M. Ahmed¹, E. Robinson⁴, M. Orton¹, J. Lunn⁴, S. Ahmad², F. McDonald⁵, I. Locke¹, D. Power³, S. Doran⁴, M. Blackledge⁴, R. Lee¹, E. Aboagye³, ¹The Royal Marsden Hospital - Chelsea, London, GB, ²Guy's & St Thomas' NHS Foundation Trust, London, GB, ³Imperial College London, London, GB, ⁴The Institute of Cancer Research, London, GB, ⁵Royal Marsden Hospital NHS Foundation Trust, London, GB
- 12:00 - 12:00 **163P - Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: Findings from the CAVE-lung trial**
C.M. Della Corte¹, M. Fasano¹, V. Ciaramella¹, F. Cimmino¹, R. Cardnell², C.M. Gay², K. Ramkumar², L. Diao², R. Di Liello¹, G. Viscardi¹, V. Famiglietti¹, D. Ciardiello¹, G. Martini¹, S. Napolitano¹, T. Troiani¹, E. Martinelli¹, J. Wang², L. Byers², F. Morgillo¹, F. Ciardiello¹, ¹Medical Oncology, Department of "Medicina di Precisione", Università degli

Studi della Campania Luigi Vanvitelli, Naples, IT, ²MDACC, Houston, US

- 12:00 - 12:00 **164P - Immune modulatory functions of lurbinectedin in small cell lung cancer and malignant pleural mesothelioma patients**
L. Cantini¹, D. Dumoulin¹, M. Vink¹, L. Klaase¹, K. Slooff¹, R. Cornelissen¹, J. Mankor¹, A.-M. Dingemans², M. Willemsen¹, J. Aerts¹, ¹Erasmus MC Cancer Institute, Rotterdam, NL, ²Erasmus MC - University Medical Center, Rotterdam, NL
- 12:00 - 12:00 **165P - Dynamic evolution of blood immune-inflammatory descriptors in advanced non-small cell lung cancer undergoing first line immunotherapy-based regimens**
G. Mazzaschi¹, M. Verzè¹, D. Tognazzi¹, B. Lorusso¹, R. Minari¹, M. Pluchino¹, F. Trentini¹, M. Manini¹, P. Bordi¹, A. Leonetti¹, F. Perrone¹, M. Corianò¹, M. Casali², I. Toscani³, A. Cosenza¹, L. Ferri¹, S. Buti¹, N. Sverzellati⁴, F. Quaini⁵, M. Tiseo¹, ¹University Hospital of Parma, Medical Oncology Unit, Parma, IT, ²AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT, ³Azienda Ospedaliera Piacenza, Piacenza, IT, ⁴University Hospital of Parma, Radiological Science, Parma, IT, ⁵University Hospital of Parma, Parma, IT
- 12:00 - 12:00 **166P - Integrated analysis reveals TP53 mutation as a biomarker of anti-PD-1/PD-L1 treatment for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma patients**
S. Wang¹, T. Xie¹, Y. Wang¹, X. Hao², P. Yuan¹, Q. Cao¹, H. Wang¹, L. Lin³, J. Ying², J. Li², P. Xing², ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN, ²Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN
- 12:00 - 12:00 **167P - KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy**
L. Pinto¹, P. Simoes Da Rocha¹, S. Clavé¹, L. Moliner², N. Navarro-Gorro¹, A. Ríos-Hoyo¹, I. Sánchez¹, M. Giner¹, A. Corbera¹, A. Taus¹, B. Bellosillo¹, E. Arriola¹, ¹Hospital del Mar - Parc de Salut Mar, Barcelona, ES, ²The Christie NHS Foundation Trust, UK, GB
- 12:00 - 12:00 **168P - Characterization of the lung tumor microenvironment upon anti-PD-L1 therapy reveals an ambiguous role for TNF- α**
K. De Ridder¹, H. Locy¹, E. Piccioni¹, M. Ibarra Zuazo², R. Awad¹, S. Verhulst³, M. Van Bulck⁴, Y. De Vlaeminck¹, Q. Lecocq¹, E. Reijmen¹, W. De Mey¹, L. De Beck¹, T. Ertveldt¹, I. Pintelon⁵, J.-P. Timmermans⁵, D. Escors², M. Keyaerts⁶, K. Breckpot¹, C. Goyvaerts¹, ¹Vrije Universiteit Brussel - Faculty of Medicine & Pharmacy, Brussels, BE, ²Immunomodulation Group, Pamplona, ES, ³Liver Cell Biology Research Group, Jette, BE, ⁴Laboratory of Molecular and Medical Oncology, Jette, BE, ⁵Laboratory of Cell Biology & Histology, Antwerp Centre for Advanced Microscopy (ACAM), University of Antwerp, Antwerp, BE, ⁶Vrije Universiteit Brussel -Faculty of Medicine and Pharmacy, In vivo Cellular and Molecular Imaging laboratory, Jette, BE

- 12:00 - 12:00 **169P - Characteristics of clonal hematopoiesis (CH) in patients with non-small cell lung cancer (NSCLC): A retrospective analysis of plasma cell-free DNA (cfDNA) comprehensive genomic profiling**
- M. Tagliamento¹, D. Vasseur², A. Bayle², M. Aldea², A. Gazzah², C. Nicotra², A. Hollebecque², D. Planchard¹, M. Frelaut², A. Botticella², A. Levy³, L. Lacroix², C. Marzac², J.B. Micol², S. Ponce², E. Rouleau², A. Italiano², B. Besse¹, ¹Institut Gustave Roussy, Villejuif, FR, ²Gustave Roussy, Villejuif, FR, ³Gustave Roussy - Cancer Campus, Villejuif, FR
- 12:00 - 12:00 **170P - Clonal hematopoiesis in asymptomatic individuals enrolled in a lung cancer screening program**
- L. Montuenga¹, P. Aguirre-Ruiz², B. Ariceta², M. Mesa-Guzman¹, L. Seijo¹, G. Bastarrica¹, B. Saez³, I. Vazquez², A. Pardo-Saganta³, M. Calasanz², J. Zulueta¹, F. Prosper¹, R. Pio³, ¹Clinica Universidad de Navarra, Pamplona, ES, ²Cima Lab Diagnostics, Pamplona, ES, ³Cima-University of Navarra, Pamplona, ES
- 12:00 - 12:00 **171P - Detection of NTRK1/2/3 rearrangements by PCR test for 5'’/3'’-end unbalanced expression**
- E. Imyanitov¹, A. Romanko¹, V. Tiurin¹, N. Mitiushkina¹, A. Venina¹, E. Preobrazhenskaya¹, R. Mulkidjan¹, A. Ivantsov¹, S. Orlov², A. Togo¹, ¹N.N. Petrov Institute of Oncology, Saint-Petersburg, RU, ²I.P. Pavlov St-Petersburg Medical University, Saint-Petersburg, RU
- 12:00 - 12:00 **173P - Genomic characteristics and its correlations with tumor mutational burden and PD-L1 expression in Chinese lung squamous cell carcinoma**
- Y. Chen¹, Q. Yang², C. Xia², S. Ding², P. Luo², C. Zhang², ¹Fujian Provincial People's Hospital, Fuzhou, CN, ²Shanghai Topgen Biomedical Technology, Shanghai, CN
- 12:00 - 12:00 **174P - Pulmonary tuft cell-like cancers across different histotypes share molecular features with potentially druggable vulnerabilities**
- Y. Yamada¹, H. Bohnenberger², M. Kriegsmann³, K. Kriegsmann⁴, S. Schölch⁵, P. Ströbel², A. Marx⁶, ¹Kyoto University Hospital, Kyoto, JP, ²Institute of Pathology, University Medical Center Göttingen, University of Göttingen, Göttingen, DE, ³Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany, Heidelberg, DE, ⁴Department of Hematology, Oncology and Rheumatology, University Hospital Heidelberg, Heidelberg, DE, ⁵Department of Surgery, University Medical Centre Mannheim, University of Heidelberg, Mannheim, DE, ⁶Institute of Pathology, University Medical Centre Mannheim and Medical Faculty Mannheim, Heidelberg University, Mannheim, DE
- 12:00 - 12:00 **175P - Mutations and clinical significance of calcium voltage-gated channel subunit alpha 1E (CACNA1E) in non-small cell lung cancer**
- G. Wang¹, S. Gao², G. Zhou³, ¹Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN, ²State Key Laboratory of Membrane Biology, Institute of Zoology, Chinese Academy of Sciences & University of Chinese Academy of Sciences, Beijing, CN, ³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

- 12:00 - 12:00 **176P - Phase transition early-invasive lung cancer and blood cell circuit**
O. Kshivets, Roshal Hospital, Roshal, RU
- 12:00 - 12:00 **177P - Feasibility and usefulness of evaluation of immune status of lung cancer patients by EBUS/TBNA cells analysis**
J. Domagala-Kulawik¹, A. Raniszewska², E. Rutkowska², R. Sokolowski², J. Bednarek², I. Kwiecien², ¹Medical University of Warsaw, Warsaw, PL, ²Military Institute of Medecine, Warsaw, PL
- 12:00 - 12:00 **178P - Germline genetic variants associated with different premalignant lesions in the bronchial epithelium**
T. Gerashchenko¹, A. Khozyainova¹, A. Schegoleva¹, R. Vorobiev¹, E. Rodionov¹, M. Artomov², E. Topolnitskiy³, N. Shefer⁴, O. Pankova¹, V. Perelmuter¹, E. Denisov¹, ¹Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RU, ²Massachusetts General Hospital, Boston, US, ³Siberian State Medical University, Tomsk, RU, ⁴Tomsk Regional Oncology Center, Tomsk, RU
- 12:00 - 12:00 **179P - Clinical profile of SMARCA4/SMARCB1-mutated non-small cell lung carcinomas: A retrospective study in a Spanish institution**
G. Fernandez, M. Antónanzas-Basa, C. Aguado De La Rosa, A. Lopez De Sa, J. Bartolomé, A. Manzano Fernández, A. Ocaña, J. Gonzalez-Larriba, Hospital Clinico Universitario San Carlos, Madrid, ES
- 12:00 - 12:00 **180P - Schwann cells promotes tumour progression in small cell lung cancer**
S. Cao, H. Zhong, Y. Zhou, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN
- 12:00 - 12:00 **181P - Anlotinib enhances the antitumor activity of high-dose irradiation combined with anti-PD-L1 by potentiating the tumor immune microenvironment in murine lung cancer**
M. Yuan, Y. Zhai, Z. Hui, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 12:00 - 12:00 **182P - Therapeutic activity of thiostrepton in patient-derived malignant pleural effusions**
B. Cunniff¹, T. Messier¹, R. Del Rio-Guerra¹, A. Kopecky², G. Scriver², G. Naumov³, ¹University of Vermont Larner College of Medicine, Burlington, US, ²University of Vermont Medical Center, Burlington, US, ³RS Oncology, Boston, US
- 12:00 - 12:00 **183P - Predictor value of PD-L1 for radiotherapy response in locally advanced non-small cell lung cancer**
V. Demircan¹, E. Acar¹, E. Senturk¹, C. Guzel¹, N. Eroglu Arkoc², N. Akyurek¹, F. Ozturk³, F. Dincbas⁴, M. Akmansu¹, ¹Gazi University - Faculty of Medicine, Ankara, TR, ²Ankara Ataturk Chest Diseases and Chest Surgery Research and Training Hospital, Ankara, TR, ³Ankara Bilkent City Hospital, Ankara, TR, ⁴Cerrahpasa Medical Faculty, Istanbul, TR

- 12:00 - 12:00 **184P - Early-stage diagnosis of lung cancer with liquid biopsy test based on peripheral blood cells**
A. Thomsen¹, S. Ott², S. Vesenbeckh², N. Calatayud³, Z. Barekati⁴, O. Schicht⁴, A. Faisst⁴, F. Staedtler⁴, J. Godau⁴, B. Woelnerhanssen², ¹Medical Center – University of Freiburg, Freiburg, DE, ²St. Claraspital, Basel, CH, ³abc biopply AG, Solothurn, CH, ⁴D Lifetec AG, Cham, CH
- 12:00 - 12:00 **185P - Clinicopathological characterization of NGS detected mutations in lung cancers: A single center experience**
J. Walter, LMU Klinikum der Universität München, Munich, DE
- 12:00 - 12:00 **186P - CIP2A modulates PKM2 dimer-tetramer transition through phosphorylation of serine 287 in non-small cell lung cancer**
L. Liang¹, Y. Zhang², D. Wang³, F. Yang³, G. Zhou³, ¹National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Balanced, CN, ²Anhui Medical University, Hefei, CN, ³National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN
- 12:00 - 12:00 **187P - Development of a magnetic nanostructure for co-delivery of metformin and silibinin on growth of lung cancer cells: Possible action through leptin gene and its receptor regulation**
D. Jafari-Gharabaghlou¹, A. Jabbari², A. Soltani², ¹Hematology & Oncology Research Center - Tabriz University of Medical Sciences, Tabriz, US, ²UMSU - Urmia University of Medical Sciences, Urmia, IR
- 12:00 - 12:00 **188P - Efficacy of SARS-CoV-2 based mRNA vaccines for patients with thoracic malignancies with 6 months follow up: A prospective observational study**
U. Janzic¹, K. Mohorcic¹, L. Mrak¹, M. Ivanovic², U. Bidovec Stojkovic¹, J. Debeljak¹, P. Korosec¹, M. Rijavec¹, ¹University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, SI, ²University Clinical centre Maribor, Maribor, SI
- 12:00 - 12:00 **189P - Assessment of seroconversion after SARS-CoV2 vaccination in patients with lung cancer**
I. Trontzas¹, I. Vathiotis¹, G. Gomatou², M. Grammoustianou², I. Tsamis², M. Anagnostakis², V. Sakka², G. Poulakou², K. Syrigos², E. Kotteas², ¹Sotiria Thoracic Diseases Hospital of Athens, Athens, GR, ²Sotiria Thoracic Diseases Hospital of Athens, ATHENS, GR
- 12:00 - 12:00 **190P - COVID-19 pandemic impact on lung cancer patient's performance status and access to treatment: A comparative study pre and during COVID-19 era**
R. Fernandes, M. Fernandes, C. Fava Gaspar, A.R. Teixeira, C. Oliveira, A. Rodrigues, I. Azevedo, Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (IPO-Porto), Porto, PT
- 12:00 - 12:00 **191P - Lung cancer care in Europe during COVID-19: Findings from a global survey of patient experience**

J. Fenemore, Global Lung cancer coalition, Manchester, GB

- 12:00 - 12:00 **192P - Randomized, phase II, placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis**
Z. Moore¹, A. Rimner¹, S. Lobaugh¹, A. Geyer¹, D. Gelblum¹, A. Shepherd¹, N. Shaverdian¹, A. Wu¹, J. Chافت¹, M. Zauderer¹, C. Rudin², N. Vander Els¹, M. Chawla¹, D. Jones¹, D. Sopka³, R. Mak⁴, Z. Liao⁵, D. Gomez¹, Z. Zhang¹, P. Paik¹, ¹Memorial Sloan Kettering Cancer Center, New York, US, ²Memorial Sloan-Kettering Cancer Center, New York, US, ³Lehigh Valley Health Network, Allentown, US, ⁴Brigham and Women's Hospital, Boston, US, ⁵MD Anderson Cancer Center, Houston, US
- 12:00 - 12:00 **193P - Safety and efficacy of immunotherapy rechallenge following a previous immune-induced interstitial lung disease**
C. Joseph¹, M. Delaunay¹, A. Lusque², J.-M. Michot³, R. Veillon⁴, M. Wislez⁵, P. Tomasini⁶, E. Giroux-Leprieur⁷, M. Duruisseaux⁸, M. Perol⁹, C. Decroisette¹⁰, B. Duchemann¹¹, S. Couraud¹², J. Milia¹, S. Collot¹, G. Prevot¹, J. Le Pavec¹³, J. Mazieres¹⁴, ¹Hôpital Larrey, Toulouse, FR, ²Institut Claudius Regaud, Toulouse, FR, ³Institut Gustave Roussy, Villejuif, FR, ⁴CHU Bordeaux, Bordeaux, FR, ⁵Hôpital Cochin, Nogent sur Marne, FR, ⁶Centre Georges-François Leclerc (Dijon), Dijon, FR, ⁷Hopital Ambroise Pare AP-HP, Boulogne-Billancourt, FR, ⁸Louis Pradel Hospital, Hospices Civils de Lyon Cancer Institute, Lyon, FR, ⁹Centre Léon Bérard, Lyon, FR, ¹⁰Le Centre Hospitalier Annecy Genevois, Metz-Tessy, FR, ¹¹Hôpital Avicenne, Bobigny, FR, ¹²Lyon Sud Hospital Center - HCL, Pierre-Bénite, FR, ¹³Hopital Saint Joseph, Paris, FR, ¹⁴Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR
- 12:00 - 12:00 **194P - Modelling strategies to combine multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer.**
F. Van Delft¹, M. Schuurbijs², M. Muller³, S. Burgers³, H. Van Rossum³, M. Ijzerman⁴, M. Van Den Heuvel², H. Koffijberg¹, ¹University of Twente, Enschede, NL, ²Radboud University Medical Center, Nijmegen, NL, ³Netherlands Cancer Institute, Amsterdam, NL, ⁴University of Melbourne Centre for Cancer Research (UMCCR) - Victorian Comprehensive Cancer Centre, Parkville, AU
- 12:00 - 12:00 **195P - Radiomics and dosiomics signature from whole lung predicts radiation pneumonitis : A model development study with prospective external validation and decision-curve analysis**
Z. Zhang¹, Z. Wang², A. Dekker², L. Wee², ¹Maastrro Clinic, Maastricht, NL, ²Maastrro, Maastricht, NL
- 12:00 - 12:00 **196P - An international consensus on actions to improve lung cancer survival: A clinical review by the international cancer benchmarking partnership (ICBP)**
C. Lynch¹, S. Harrison¹, J. Butler², D.R. Baldwin³, P. Dawkins⁴, J. Van Der Horst⁵, E. Jakobsen⁶, J. Mcaleese⁷, A. Mcwilliams⁸, K. Redmond⁹, A. Swaminath¹⁰, C. Finley¹¹, ¹Cancer Research UK, London, GB, ²Royal Marsden NHS Foundation Trust, London, GB, ³City Hospital Campus - Nottingham University Hospitals NHS Trust, Nottingham, GB, ⁴Middlemore Hospital, Auckland, NZ, ⁵Glasgow Royal Infirmary, Glasgow, GB, ⁶Odense University Hospital, Odense, DK, ⁷Belfast City Hospital, Belfast, GB, ⁸Fiona Stanley Hospital, Perth, AU, ⁹Mater Misericordiae University Hospital, Dublin, IE, ¹⁰McMaster

University, Hamilton, CA, ¹¹St Joesph's Healthcare Hamilton, Hamilton, CA

- 12:00 - 12:00 **197P - Lung cancer in lung transplant recipients**
M. Svorcova, L. Valentova-Bartakova, J. Havlin, L. Mendez, J. Vachtenheim, K. Vyskocilova, T. Kotowski, J. Pozniak, J. Kolarik, J. Simonek, R. Lischke, Prague Lung Transplant Program, University Hospital Motol, Prague, CZ
- 12:00 - 12:00 **198P - Association between BTLA polymorphisms and NSCLC risk**
A. Andrzejczak¹, A. Partyka¹, A. Wisniewski¹, I. Porebska², K. Pawelczyk³, M. Jasek¹, L. Karabon¹, ¹Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, PL, ²Wroclaw Medical University, Wroclaw, PL, ³Lower Silesian Centre of Lung Diseases, Wroclaw, PL
- 12:00 - 12:00 **199P - The relative impact of surgery history on cancer risk in patients less than 60 years old**
H. Wang, J. Li, S. Xiong, Z. Yu, F. Li, R. Zhong, C. Li, H. Liang, H. Deng, Z. Chen, B. Cheng, W. Liang, J. He, State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, CN
- 12:00 - 12:00 **200P - The value of holistic assessment and rapid intervention: The lung cancer outpatient occupational therapy service (LCOOTS)**
J. Welford, NUTH - Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, GB
- 12:00 - 12:00 **201P - Readability of thoracic surgery consent forms in Queensland, Australia**
S. Dutta, A. Iyer, Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU